Key Takeaways Boeing Global Services revenues rose 6% to $5.4B in Q1, driven by government and aftermarket demand.Boeing Global Services delivered $971M in operating earnings and an 18.1% operating margin.Boeing Global Services ended Q1 with a record $33B backlog, boosting revenue visibility. The Boeing Company’s (BA - Free Report) Global Services ("BGS") segment is increasingly becoming an important contributor to the company's recovery and long-term growth strategy.
During the first quarter of 2026, BGS generated revenues of $5.4 billion, representing a 6% increase from the prior-year period’s level. The growth was primarily driven by higher government-related service activity and continued demand for aviation aftermarket solutions. While Boeing's commercial aircraft business remains cyclical and heavily dependent on production rates, the services segment provides a more stable source of recurring revenues.
BGS generated operating earnings of $971 million, resulting in an operating margin of 18.1%. Although margins declined modestly from the prior year due to the impact of the Digital Aviation Solutions divestiture, the segment continues to generate significantly higher margins than Boeing's commercial and defense operations. This demonstrates the attractive economics of maintenance, repair, parts distribution, training, and digital aviation services.
Several strategic developments during the quarter further strengthened the business. Boeing inked the largest-ever Landing Gear Exchange Program agreement with Singapore Airlines Group and received initial FAA and EASA qualification for 777-9 training devices. These wins highlight Boeing's ability to monetize its growing installed aircraft base through long-term support contracts and training solutions.
BGS ended the quarter with a record backlog of $33 billion, providing substantial revenue visibility and demonstrating sustained customer demand across both commercial and government markets. As airlines continue to expand fleets and defense customers seek long-term maintenance support, Boeing appears well positioned to benefit from growing aftermarket spending.
Companies Expanding Aftermarket and Services BusinessesGrowing global aircraft utilization continues to increase demand for maintenance, repair, overhaul, and aviation support services. Several aerospace companies benefiting from this trend are discussed below:
Airbus SE (EADSY - Free Report) continues to expand its services portfolio through Airbus Services, offering maintenance, training, fleet management, and digital solutions to airline customers worldwide. The company increasingly views services as a key contributor to long-term profitability.
RTX Corporation (RTX - Free Report) maintains one of the aerospace industry's largest aftermarket businesses through its Collins Aerospace and Pratt & Whitney units. The company's growing installed base of engines and aircraft systems supports recurring revenues from maintenance, spare parts and repair services.
BA Stock’s Earnings EstimatesThe Zacks Consensus Estimate for 2026 and 2027 EPS indicates a year-over-year improvement of 98.6% and 2,813.2%, respectively.
Image Source: Zacks Investment Research
BA Stock Trades at a DiscountIn terms of valuation, BA’s forward 12-month price-to-sales (P/S) is 1.6X, a discount to the industry’s average of 2.54X.
Image Source: Zacks Investment Research
BA Stock’s Price PerformanceIn the past three months, the company’s shares have risen 2.1% against the industry’s 8.5% decline.
Image Source: Zacks Investment Research
BA’s Zacks RankThe company currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The market's perception of The Boeing Company NYSE: BA remains anchored to a narrative of regulatory friction and production stalls. While retail sentiment is paralyzed by legacy headline risk, the aerospace sector giant quietly delivered 60 commercial aircraft in May, a 33% year-over-year (YOY) surge that mechanically drives the free cash flow required for aggressive balance sheet deleveraging.
Boeing Today
$219.22 -2.41 (-1.09%)
As of 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$176.77▼
$254.35P/E Ratio106.42
Price Target$262.32
This post-strike production high indicates that manufacturing bottlenecks are resolving, offering buyers an asymmetric entry point into a duopoly operating with a massive global backlog.
Get Boeing alerts:
The disconnect between factory output and stock valuation has created a compelling opportunity for investors who prioritize operational data over media sentiment. At Boeing's current share price, the market appears to be pricing in continued disruption rather than the emerging reality of a stabilized and accelerating industrial machine.
For investors willing to look past the noise, the foundational metrics of a powerful industrial turnaround are aligning.
From Factory Floor to Free Cash FlowFor an industrial titan like Boeing, deliveries are the ultimate arbiter of financial health. Each aircraft handover triggers final customer payment, injecting high-margin revenue directly into the treasury. The May delivery of 60 jets, with 51 being the critical 737 MAX narrowbody, is the most concrete evidence yet that Boeing is moving past the wiring defects and supplier constraints that previously capped output. This operational cadence is fundamental to achieving management's stated fiscal year 2026 free cash flow (FCF) target of $5 billion.
Understanding the importance of this FCF generation is critical, especially when analyzing Boeing's balance sheet. Boeing currently has a debt-to-equity ratio of 7.42, which requires robust, predictable cash flow to manage effectively. The recent 14% YOY revenue growth reported in the first quarter of 2026, which led to an earnings-per-share figure that handily beat consensus estimates, demonstrates the powerful earnings leverage that comes from scaling production against fixed costs.
As Boeing continues to smooth out its supply chain, particularly with key fuselage suppliers, reduced rework hours per airframe should translate into further margin expansion. This is the core of the bull thesis: as deliveries normalize, cash flow swells, allowing for rapid deleveraging and a fundamental re-rating of Boeing's valuation.
Boeing's Revenue Is More Secure Than You ThinkWhile the current production ramp provides immediate financial relief, two recent catalysts have significantly de-risked Boeing's long-term revenue and backlog profile.
First, the U.S. Federal Aviation Administration (FAA) granted Type Inspection Authorization for the 777X program in early June. This initiates the final phase of flight testing for the next-generation widebody jet. Securing this regulatory milestone clears a path for late 2026 certification and the commencement of highly profitable 777X deliveries in 2027, unlocking a new and vital product cycle.
Second, a landmark agreement confirmed a Chinese order for 200 Boeing aircraft. For years, geopolitical tensions had largely sidelined Boeing from one of the world's fastest-growing aviation markets, allowing its primary competitor, Airbus OTCMKTS: EADSF, to gain significant ground.
This new order signals a crucial reopening of a multi-billion-dollar sales channel, adding substantial depth and visibility to Boeing's production backlog for years to come. These two events provide a powerful defense against the bearish argument that the current recovery is temporary, cementing a clear and durable path to future earnings growth.
Insiders and Institutions Are Quietly Boarding BoeingOverall MarketRank™77th Percentile
While retail investors may be hesitant, institutional players and corporate insiders appear to be positioning for an upside move.
The options market reveals a telling trend, a significant build-up of open interest in the January 2027 $250 call options. This positioning suggests that sophisticated investors are hedging against, or speculating on, a sharp share price appreciation that would push Boeing well above its current trading range and closer to the average analyst price target of $259.80.
Further reinforcing this view is the low level of short interest, currently around 2% of the float. Despite the negative headlines, institutional bears are demonstrating a clear unwillingness to bet against the fundamental operational recovery underway.
Perhaps the most compelling signal comes from within Boeing itself. On May 23, 2026, Boeing Director Bradley Tilden acquired 1,370 shares on the open market. Insider buying from a director is a powerful vote of confidence in Boeing's strategic direction and future valuation. When insiders with the most intimate knowledge of a company's operations are willing to invest their own capital, it sends an unambiguous message to the market about their conviction in the long-term value proposition.
What Boeing's Turnaround Means for Your WatchlistFor investors focused on industrial turnarounds, Boeing presents a case where the underlying financial and operational metrics are improving far more rapidly than the public narrative suggests. The confluence of accelerating deliveries, a de-risked product pipeline, and clear signals of institutional accumulation suggests that the worst of the turbulence may be passing.
Potential headwinds, including persistent supply chain vulnerabilities and any renewed regulatory scrutiny, remain notable risks that warrant careful monitoring.
However, the data points to an inflection point. The operational momentum seen in May provides a tangible foundation for financial recovery and balance sheet repair. Investors looking for a long-term position in a global industrial champion might consider the current disconnect between sentiment and reality as a window of opportunity.
Those convinced by the operational turnaround may find the current valuation an attractive entry point for a long-term hold, while more cautious investors might add Boeing to their watchlist to monitor for continued delivery consistency and margin improvement in the upcoming quarters.
Should You Invest $1,000 in Boeing Right Now?Before you consider Boeing, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boeing wasn't on the list.
While Boeing currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
NEW YORK--(BUSINESS WIRE)--Citigroup Inc. is announcing the redemption, in whole, constituting $2,750,000,000 of its 1.462% Fixed Rate / Floating Rate Notes due 2027 (the “fixed rate/floating rate notes”) (ISIN: US172967NA50) and the redemption, in whole, constituting $400,000,000 of its Floating Rate Notes due 2027 (the “floating rate notes” and, together with the fixed rate/floating rate notes, the “notes”) (ISIN: US172967MZ11).
The redemption date for the notes is June 9, 2026 (the “redemption date”). The cash redemption price for the notes payable on the redemption date will equal par plus accrued and unpaid interest, to but excluding, the redemption date.
The redemptions announced today are consistent with Citigroup's liability management strategy and reflect its ongoing efforts to enhance the efficiency of its funding and capital structure. Citigroup will continue to consider opportunities to redeem or repurchase securities, based on several factors, including without limitation, the economic value, regulatory changes, potential impact on Citigroup's net interest margin and borrowing costs, the overall remaining tenor of Citigroup's debt portfolio, capital impact, as well as overall market conditions.
Beginning on the redemption date, interest will no longer accrue on the notes.
Citibank, N.A. is the paying agent for the notes. For further information on the fixed rate/floating rate notes, please see the related prospectus supplement at the following web address: https://www.citigroup.com/rcs/citigpa/akpublic/storage/public/146due060927.pdf
For further information on the floating rate notes, please see the related prospectus supplement at the following web address: https://www.citigroup.com/rcs/citigpa/akpublic/storage/public/FRNdue060927.pdf
About Citi
Citi is a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management and a valued personal bank in its home market of the United States. Citi does business in more than 180 countries and jurisdictions, providing corporations, governments, investors, institutions and individuals with a broad range of financial products and services.
Additional information may be found at www.citigroup.com | X: @Citi | LinkedIn: www.linkedin.com/company/citi | YouTube: www.youtube.com/citi | Facebook: www.facebook.com/citi
Banks have spent years launching artificial intelligence (AI) chatbots and virtual assistants. Citigroup’s latest deployment is less visible and more valuable: an AI document-processing system that compresses account opening review time from over an hour to 15 minutes.
Tim Ryan, the bank’s head of technology, told Reuters in April that the improvement is part of a broader push to automate compliance-heavy workflows across the institution.
The use case is one of roughly 50 processes the bank has flagged for automation, with client and employee onboarding and know-your-customer (KYC) compliance among the first in line. Ryan told Reuters the same tools compressing review times are also automating coding, testing and legacy system migration.
Why Account Opening Is the Right Problem Account opening sits at the intersection of every operational bottleneck a large bank carries. It requires document collection, identity verification, sanctions screening, KYC checks and data entry across systems that rarely communicate cleanly. Manual review doesn’t just slow the process. It introduces errors, creates compliance exposure and consumes staff time that could be better used elsewhere.
Ryan told Reuters Citi has identified roughly 50 critical internal processes for review and automation. Client and employee onboarding are among the first. The bank’s tech workforce now numbers around 50,000 people, he said, with more software engineers hired as it shifts away from contractors.
What the 15 Minutes Actually Means The 75% reduction in review time isn’t a one-account result. The services division handles institutional and corporate clients, where documentation requirements are dense and volumes are high. Citi’s annual report detailed that the bank has empowered more than 182,000 employees with proprietary AI tools and provided 30,000 developers with AI tools generating approximately 100,000 hours of weekly capacity.
Advertisement: Scroll to Continue
Faster review means earlier revenue recognition on new client relationships, fewer errors from manual data entry and compliance staff spending less time on routine document checks. Ryan told Reuters the bank plans to use AI to migrate data from legacy systems, automate coding and test more and faster. Account opening is the use case Citi chose to disclose. The list of 50 targeted processes suggests the ambition runs further.
PYMNTS Intelligence found that 85% of financial services firms are increasing AI budgets over the next 12 months, with productivity and efficiency gains cited as the top justification by 65%. Yet AI adoption for KYC and identity verification across the industry sits at just 20%, the report found, meaning the gap Citi is closing is still wide open at most institutions.
Last month, PYMNTS reported that financial institutions are adopting AI more deeply, with emphasis on back-office functions where data is structured, outcomes are measurable and the return on investment is easier to quantify.
South32 Ltd (LSE:S32, ASX:S32, OTC:SHTLF) is Citi's preferred mining stock as the bank becomes more bullish on copper and aluminium prices, while Glencore PLC (LSE:GLEN) is its favoured way to play the copper theme among the major diversified miners.
The US bank has raised its long-term copper forecasts and now expects prices to reach $15,000 a tonne within the next year, versus a current LME price below $13,800.
Citi's view is based on support from supply shortages extending into 2027 and 2028.
That outlook has prompted a series of target price upgrades across the sector. Citi increased its target price on South32 to 320p from 300p, while lifting BHP Group Ltd (LSE:BHP, ASX:BHP) to £35 from £29 and Rio Tinto Ltd (LSE:RIO, ASX:RIO, OTC:RTNTF) to £81 from £76.
Versus BHP or Rio, the bank's analysts argued that Glencore "among global diversifieds as better exposure to copper upside", though Anglo American PLC (LSE:AAL) and Antofagasta PLC (LSE:ANTO) are viewed by investors as the FTSE 100 miners to buy for copper exposure.
Citi maintained 'neutral' ratings on BHP and Rio Tinto, saying the benefits from higher copper prices are partly offset by a more subdued outlook for iron ore, which remains a major earnings driver for both groups.
By contrast, South32 continues to stand out because of its exposure to both copper and aluminium, where Citi also sees upside. The company's Hermosa project in Arizona was highlighted as a source of long-term structural growth.
Citi said consensus earnings forecasts for South32 still have room to move higher as analysts incorporate stronger assumptions for copper and aluminium prices.
The bank expects the company to be one of the biggest beneficiaries of commodity price upgrades over the next two years.
Key Takeaways C expects 5-6% y/y NII growth in 2026, excluding Markets, driven by stronger core earnings.Citigroup benefits from loan growth in Cards and Wealth, and rising deposits supporting NII expansion.C gains from its transformation plan, $2-$2.5B savings and lower funding-cost pressure supporting NII. Citigroup, Inc. (C - Free Report) expects its net interest income (NII), excluding Markets, to grow 5-6% year over year in 2026, supported by improving loan demand, stabilizing deposit costs and disciplined balance-sheet management. The outlook reflects the bank’s efforts to benefit from a more favorable rate and funding environment while continuing to reshape its business toward higher-quality growth.
A key driver is the improvement in loan and deposit trends. At the end of the first quarter of 2026, Citigroup reported $761.6 billion in loans, up 1% sequentially, and $1.45 trillion in deposits, up 3% from the prior quarter. This steady balance-sheet growth provides a stronger base for interest income generation. In the first quarter of 2026, NII rose 12% year over year to $15.7 billion, while NII excluding Markets increased 7% to $12.9 billion, indicating solid momentum heading into the rest of the year.
For 2026, management expects strong loan growth in Cards and Wealth businesses, driven by continued product innovation, solid customer engagement and its high-quality card portfolio, which is further expected to support NII expansion. Citigroup is also likely to benefit from stabilizing funding costs.
After initial monetary easing in 2024 and three rate cuts in 2025, the Federal Reserve has kept rates steady so far in 2026. As such, lower rates are easing pressure on deposit costs while allowing the bank to capture better spreads as loan demand improves.
The company’s broader transformation plan further supports the NII growth target. Citigroup is simplifying operations, exiting non-core consumer businesses and reallocating resources toward core franchises. These moves are expected to generate $2-$2.5 billion in annualized savings by 2026 and help the company deliver positive operating leverage.
Overall, Citigroup’s 5-6% NII growth goal rests on three pillars: balance-sheet growth, lower funding-cost pressure and a leaner operating model focused on core banking opportunities.
What Do C’s Peers Say About Their 2026 NII Expectations?Bank of America (BAC - Free Report) and JPMorgan (JPM - Free Report) are two peers of Citigroup, which also expects their NII to grow in 2026.
Bank of America indicated that 2026 NII could reach the upper end of 6-8% growth. Bank of America expects growth to be driven by higher yields on fixed-rate assets and steady consumer spending.
JPMorgan expects NII to reach $103 billion in 2026, even as it builds against a lower rate backdrop. Part of the lift is likely to come from Markets NII. JPMorgan expects 2026 NII, excluding Markets, of $95 billion, implying Markets NII of $8 billion, an area that can be more variable than the core lending-and-deposit engine.
C’s Price Performance & Zacks RankShares of Citigroup have gained 69.5% over the past year compared with the industry’s growth of 27%.
Image Source: Zacks Investment Research
Currently, C carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
As we ready up for a hot summer, many investors seem ready for the stock markets to really heat up. With Citigroup (NYSE:C | C Price Prediction) strategist Scott Chronert — a man who has a pretty solid track record — recently raising the bar on its S&P 500 price targets, now expecting the index to climb all the way to 8,100, a rise of around 9.5% from current levels, questions linger as to what the shape of the chart will be to get there.
Of course, a summertime surge or “melt-up” can’t be ruled out just because the semiconductors caused the S&P 500 and Nasdaq 100 to experience their worst single-day drop in a while. But, at the same time, it still feels like we’re in the midst of one of the least-loved market rallies.
Whether that’s because of the bearish headlines, the stretched valuation metrics, or doubts that AI CapEx will ultimately pay off in a timeline that’s quick enough, I do think you have to respect the resilience of Mr. Market, especially as the conflict in Iran continues. While hike price targets on the S&P are encouraging, I certainly wouldn’t look to get too bullish, especially given the risks that the semiconductors could, once again, drag down the broad markets once the trade reverses course.
Even with the iShares Semiconductor ETF (NASDAQ:SOXX) turning higher on Monday, gaining 6%, or close to half of the ground lost on Friday’s turbulent session, I think it’s a tad too early to be racing for the hills when it comes to the AI trade, especially as the supercycle enters its next stages.
The AI supercycle is alive and well. That’s enough reason to stay invested as the market stays active into the summer While Citi highlighted the AI boom or “supercycle” as part of its year-end price target hike (a 9.5% gain is pretty good for six months or so!), I do think the debut of some massive AI IPOs is going to generate some pretty significant, perhaps off-the-charts trading volume.
Indeed, that looming SpaceX (SPCX) IPO, which is now days away, is going to cause more than just a ripple across the market. I think it could cause a tsunami, as investors move money out of some names and into SpaceX, as well as other plays tied to the monetization phase of the AI revolution.
As a part of Citi’s S&P price target hike, they argue that it’s earnings, rather than just multiple expansion (like what we’ve witnessed in the past year), that could do more of the talking. A wide range of companies have real AI strategies and, what’s more, they have real milestones to target. As more firms set a dollar amount for their AI-related goals, I think the AI supercycle could enter a new kind of phase, one where applications actually make big money after the hardware has been spent and put to good use.
In any case, given the year-end price target rise, I think investors should care less about the specifics of the timing (whether the majority of the gains come in summer or into fall and winter) and more about staying invested.
The bottom line After a session like Friday, it’s easy to worry, but with SpaceX poised to make waves for the next couple of weeks and months that follow the big IPO, my guess is that the summer of 2026 could have the potential to be far more liquid than prior summers.
Whether it’s heated, though, remains the big question. I have no idea, nor does anyone else. But I think it matters less, considering what could be in the cards for the rest of the year and going into 2027.
Like it or not, SpaceX’s $1.77+ trillion landing is a major market liquidity event. And one that could make this summer far less quiet as the AI boom progresses and Elon Musk’s innovations get put under the microscope. For traders, there’s just too much happening to vacation without having that app open.
Citigroup has hired Andrew Conway as its global chair of consumer and retail investment banking to expand its banking franchise in the sector, according to a memo seen by Reuters.
Key Takeaways Citigroup says its turnaround is moving from remediation to execution, growth and efficiency focus.C is driving expense discipline through automation, AI tools and the removal of stranded costs.C expects strong Q2'26 trading revenue growth and mid-teen IB fee gains as client activity improves. Citigroup Inc. (C - Free Report) management’s latest commentary suggests that CEO Jane Fraser’s turnaround strategy is moving into a new phase, from repair and remediation toward execution, efficiency and growth. Speaking at the Morgan Stanley U.S. Financials Conference held yesterday, chief financial officer Gonzalo Luchetti emphasized that C is now focused on client-driven growth, stronger operating performance, disciplined capital use and a culture of accountability.
Management highlighted that the bank has spent the past several years simplifying operations, strengthening controls and addressing structural issues that had weighed on its performance. With approximately 90% of its transformation initiatives either completed or nearing completion, Citigroup is now increasingly shifting its attention to improving returns and driving durable revenue growth across its core businesses.
Expense discipline remains central to the turnaround. Citigroup expects to benefit from lower stranded costs, reduced temporary transformation spending and structural efficiencies from automation, technology and artificial intelligence. Management said that more than 100 large-scale manual processes are being reviewed for automation, with senior leaders monitoring progress weekly.
AI is already producing measurable benefits across the company. In customer service, Citigroup has reduced call times by about 60 seconds using generative AI, while CitiDirect agents have improved containment rates by roughly 50%. In credit cards, AI and machine learning have helped improve approval rates by about 100 basis points. The bank is also continuing to invest in targeted growth areas, including markets, investment banking, wealth, cards and services.
Against this backdrop, management reaffirmed several key 2026 outlooks. C expects net interest income, excluding markets, to grow 5-6% this year. The bank also remains on track to achieve an efficiency ratio of 60% and a return on tangible common equity (ROTCE) of 10-11% in 2026.
Solid Trading & Investment Banking OutlooksAt the conference, Citigroup signaled stronger momentum in its markets business. The bank expects second-quarter 2026 trading revenues to rise in the high-single-digit to low-double-digit range year over year despite comparing against a strong second-quarter 2025 base that included tariff-driven volatility. The expected trading revenue increase is being driven by strength across equities, prime finance, derivatives, currencies and commodities, along with solid volumes in financing and securitization. Luchetti said that client engagement remains “good and intense,” continuing the momentum Citigroup saw in the first quarter.
For Citigroup, the strength in markets is an important proof point. The bank has been investing in its equities platform while maintaining its historical strength in fixed income. Management pointed to equities, prime finance and derivatives as areas aligned with C’s strategy to scale the business, while fixed income continues to benefit from strength in currencies and commodities.
Investment banking (IB) is also showing signs of recovery. C expects IB fees to grow in the mid-teens year over year in the second quarter of 2026, supported by stronger equity capital market activity, including IPOs and follow-on offerings.
Similar to Citigroup, Bank of America (BAC - Free Report) and JPMorgan (JPM - Free Report) expect their IB and trading revenues to improve in the second quarter of 2026.
Bank of America’s trading revenues are expected to jump 15% year over year in the second quarter of 2026, driven by higher client activity and market volatility. BAC also highlighted that its IB pipelines remain “pretty good,” supported by steady deal-making activity.
JPMorgan’s IB fees could rise nearly 10% or more year over year in the second quarter of 2026, reflecting improving deal pipelines and stronger capital markets activity, although higher expenses may limit operating leverage. Further, JPMorgan noted that its markets business, which includes its trading operations, is also on track to grow 11% in the second quarter and could perform "a little better" than that forecast.
Final Words on CCitigroup’s latest outlook suggests that the bank’s transformation is gaining traction. The turnaround is increasingly being measured not only by cost reductions and remediation progress, but also by stronger revenue momentum, improved operating efficiency and disciplined capital deployment.
Despite ongoing macroeconomic uncertainties, including geopolitical risks and potential shifts in interest rates, management pointed to continued strength in client activity, resilient consumer spending and stable credit trends. With trading revenues poised for a solid increase and Citigroup reaffirming its 2026 financial targets, the latest update provides evidence that Fraser’s strategy is beginning to translate into improved operating performance.
Citigroup Price Performance & Zacks RankC shares have gained 71.9% in the past year compared with the industry’s growth of 27.3%.
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
President Donald Trump congratulated Citigroup and CEO Jane Fraser for being the top adviser on mergers and acquisitions. But the bank is nowhere near the top of the list in the first quarter and has actually slipped.
Citigroup outperformed the broad market as well as some other major bank stocks Wednesday after President Donald Trump lauded the bank and its CEO Jane Fraser in a social media post.
At 9:30 a.m. ET, Trump praised Citigroup on Truth Social, writing: "Wow! CITI was ranked Number 1 in topping M&A Advisory Market by Value in Q1. Congratulations to Jane F and ALL of her great people. They've worked really hard! BIG comeback for CITI!!! President DONALD J. TRUMP"
The president's post went up just as the stock market was opening, and at one point Citigroup shares touched a high of $137.12, up almost 1.8%. By the end of the day, however, Citi fell 1%, still less than JPMorgan and Goldman Sachs and the S&P 500.
It wasn't immediately clear which investment banking league rankings President Trump was referring to. So far in 2026, for example, Goldman Sachs, JPMorgan, Morgan Stanley and BofA Securities all rank ahead of Citigroup in the latest Global M&A Advisor Ranking on Dealogic, a leading financial analytical platform.
While Goldman Sachs was the lead advisor on 196 deals worth a combined $992.3 billion this year, Citi was the lead on 97 deals worth $285.3 billion.
In fact, according to Dealogic, Citigroup has fallen to number 5 among leading mergers and acquisitions advisors in 2026, down from number 4 in 2025.
Leon Kalvaria, Citigroup's global chair for banking, appeared on Fox Business News early Wednesday, where he was asked about Citi's position as the leading advisor on power sector deals. Citi advised on four deals worth a combined $41.4 billion in the energy industry so far in 2026, according to Global Data Financial Deals Database.
What is clear is that Citigroup stock has outperformed the S&P 500 this year, climbing 14.3% against an S&P 500 gain of 6.2%, according to FactSet data. By contrast, Wells Fargo is down 12.1%, JPMorgan is lower by 4.1% and Bank of America is off 1% in 2026. Goldman is 13.9% higher, also trailing Citi.
Citigroup is in the midst of a multiyear turnaround under Fraser, involving streamlining business units, cutting jobs and focusing on high-margin markets and services. The stock has risen for three straight years after jumping more than 70% in 2025, almost 42% in 2024 and 19% in 2023.
Citigroup launched tokenized depositary receipts that are designed to broaden access to private markets.
The new Digital Depositary Receipts on private shares provide investors with direct access to private companies’ equity through a familiar investment structure and offer private companies access to liquidity through expanded investor outreach, the bank said in a Thursday (June 11) press release.
Citi is collaborating with SIX, a fully regulated digital central securities depositary, and will use that company’s blockchain infrastructure. The bank will serve as a custodian on the platform and will be responsible for the settlement and safekeeping of the tokenized depositary receipts, according to the release.
Citi is considering extending the offering across other financial market infrastructures and blockchain networks, per the release.
Bis Chatterjee, head of partnerships and innovation, services at Citi, said in the release that this new offering helps meet the need for diverse and trusted access points to private markets as those markets continue to grow.
“Our Digital Depositary Receipts product is designed to provide superior client service, safeguard assets and facilitate capital markets activity with the same rigor that underpins traditional financial markets,” Chatterjee said. “The interoperability of the product will further enable Citi to support a wider range of issuers and investors as digital asset market infrastructure continues to evolve.”
Advertisement: Scroll to Continue
Deborah Querub, head of digital assets for Wealth at Citi, said in the release: “We’re focused on responsibly expanding access to new types of investment opportunities while preserving the structures, protections and experience our clients expect.”
The new solution’s first transaction was between Citi portfolio company Kaleido, which is an institutional tokenization and digital asset platform, and investors within its Wealth business, the release said.
Kaleido Founder and CEO Steve Cerveny said in the release that private companies like Kaleido are scaling faster than the structures for private market capital formation.
“Citi’s Digital Depositary Receipts allow us to explore new paths for growth while keeping the agility that makes private companies competitive, and that’s an advantage for founders planning long term,” Cerveny said.
PYMNTS reported June 4 that Citigroup is among the major commercial banks that plan to launch a tokenized deposit network in the first half of 2027. The network will be operated by The Clearing House, the real-time payment company co-owned by the same banks.
Chatterjee told PYMNTS in an interview posted in April that executives in the banking sector are increasingly confident that tokenized deposits could become the preferred on-chain dollar for institutional and wholesale use.
For all PYMNTS digital transformation coverage, subscribe to the daily Digital Transformation Newsletter.
Citigroup has made another hire this week to strengthen its consumer and retail investment banking group, with Ryan Beaupré joining as a managing director, according to a memo seen by Reuters on Thursday. A spokesperson from Citi confirmed the contents of the memo.
Key Takeaways Citigroup launched Digital Depositary Receipts to provide access to private company shares.C completed the first DDR transaction involving Kaleido and investors from its Wealth business.C's DDR platform combines issuance, custody and settlement in a single framework. In a notable move within the evolving digital assets space, Citigroup Inc. (C - Free Report) has launched Digital Depositary Receipts (DDRs) on private company shares. This creates a new avenue for issuers and investors to participate in private markets.
The new structure is designed to simplify private market investing by bringing issuance, custody and settlement under a single platform. By serving as both issuer and custodian of the tokenized depositary receipts, C aims to reduce the complexity and costs that are often associated with traditional private market transactions.
The company also completed the first transaction on the platform involving Kaleido and investors from its Wealth business. The transaction highlights its efforts to expand private market access while leveraging its wealth management, custody and securities services franchises.
Details of C’s Digital Depositary Receipts PlatformThe company's DDRs are tokenized instruments that provide investors with exposure to private company shares through a familiar depositary receipt structure.
The offering is designed to help private companies raise capital and provide liquidity opportunities for existing shareholders without pursuing a public listing. At the same time, companies retain control over ownership rights and shareholder records. The structure also provides an institutional-grade alternative to traditional private market arrangements.
Built on C's established Depositary Receipts and Custody businesses, the platform uses blockchain infrastructure operated by SIX to issue, settle and safeguard tokenized securities while reducing reliance on multiple intermediaries and special-purpose vehicles commonly used in private market transactions.
For wealth clients, the product is integrated into C's existing wealth platforms, allowing access to private company investments through a familiar investment structure while maintaining institutional safeguards and compliance standards.
Rationale Behind C’s Latest Tokenized DDR LaunchThe launch reflects growing structural changes in global capital markets, particularly the prolonged timeline for Initial Public Offerings (IPOs) and increasing demand for private market liquidity solutions.
Employees and early investors in private companies often have limited options to sell their holdings and access liquidity, forcing them to rely on fragmented secondary markets. Citigroup's DDRs address this gap by offering a more standardized, scalable and regulated framework for accessing private markets.
The model also simplifies capital formation and investor distribution without requiring a public listing, allowing companies to raise capital while maintaining control over ownership and governance structures.
The latest launch builds on C's broader efforts to expand its digital asset and tokenization capabilities. In 2025, the company partnered with SDX to develop a platform for tokenizing and distributing pre-IPO equities on regulated digital market infrastructure, further expanding its presence in private market tokenization. In 2024, it introduced the Citi Integrated Digital Assets Platform, which supports the issuance, custody and management of tokenized financial instruments.
These initiatives, along with the launch of DDRs, reinforce Citigroup's position in the evolving private markets ecosystem while supporting fee-based revenue growth across custody, issuance, settlement and wealth management services.
C’s Price Performance & Zacks RankOver the past six months, shares of Citigroup have gained 22.4% compared with the industry’s growth of 1.4%.
Image Source: Zacks Investment Research
Citigroup currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Firms’ Efforts to Expand Digital Asset InitiativesMajor financial firms, including Franklin Resources, Inc. (BEN - Free Report) and State Street Corporation (STT - Free Report) , have also been advancing their digital asset capabilities.
Last week, Franklin Templeton, the asset management arm of Franklin Resources, partnered with MoonPay to expand the distribution of its tokenized money market funds. The partnership integrates Franklin Templeton's Benji platform with MoonPay's trading infrastructure, allowing eligible institutions to move between stablecoins and tokenized fund products more efficiently while broadening access to digital investment solutions.
In January 2026, State Street launched its Digital Asset Platform, a secure infrastructure designed to support tokenized assets, tokenized money market funds, exchange-traded funds, tokenized deposits and stablecoins. The platform provides wallet management, custody and cash capabilities, enabling institutional clients to access digital asset services through an integrated and compliant framework.
Nike Inc (NYSE:NKE, XETRA:NKE) is leaning on its football division to sustain the brand's ongoing turnaround, positioning the category as the next major proof point following a successful revival in running, according to analysts who attended a company investor event in New York.
Jefferies analysts, after attending Nike's Global Football investor event, said it reinforced CEO Elliott Hill's strategy of rebuilding the brand one sport and one region at a time.
Nike showcased a full range of federation kits and cleats anchored by Aero-FIT, a new platform designed to deliver higher airflow and scale across sports. The cleat lineup spans the Mercurial, Phantom, Tiempo, and Vapor franchises at multiple price points. New launches including updated Tiempo and Mercurial lines are intended to signal a return to consistent product cadence and category leadership.
The company is also overhauling its marketing approach, building what it describes as a connected football "universe" anchored by a campaign called "Rip the Script." The campaign spans athletes, cities, and culture with a 12-week activation schedule tied to the upcoming World Cup. Distribution is being upgraded simultaneously, with Nike elevating roughly 6,000 doors across wholesale and owned retail to increase brand visibility during the tournament window.
Jefferies analysts said the strategy mirrors the running playbook: lead with performance storytelling and better product in higher-quality retail doors to convert consumer engagement into purchase.
Beyond the tournament itself, Nike is positioning football as a multi-year growth engine spanning footwear, apparel, and streetwear. The company is aiming to build a unified football marketplace that extends from on-pitch performance to street culture, sustaining demand beyond the World Cup cycle.
The analysts remain constructive on Nike's turnaround but cautioned that execution is uneven, with China, Europe, and direct-to-consumer still works in progress. A full earnings recovery is not expected before fiscal 2028.
Nike Inc (NYSE:NKE, XETRA:NKE) is leaning on its football division to sustain the brand's ongoing turnaround, positioning the category as the next major proof point following a successful revival in running, according to analysts who attended a company investor event in New York.
Jefferies analysts, after attending Nike's Global Football investor event, said it reinforced CEO Elliott Hill's strategy of rebuilding the brand one sport and one region at a time.
Nike showcased a full range of federation kits and cleats anchored by Aero-FIT, a new platform designed to deliver higher airflow and scale across sports. The cleat lineup spans the Mercurial, Phantom, Tiempo, and Vapor franchises at multiple price points. New launches including updated Tiempo and Mercurial lines are intended to signal a return to consistent product cadence and category leadership.
The company is also overhauling its marketing approach, building what it describes as a connected football "universe" anchored by a campaign called "Rip the Script." The campaign spans athletes, cities, and culture with a 12-week activation schedule tied to the upcoming World Cup. Distribution is being upgraded simultaneously, with Nike elevating roughly 6,000 doors across wholesale and owned retail to increase brand visibility during the tournament window.
Jefferies analysts said the strategy mirrors the running playbook: lead with performance storytelling and better product in higher-quality retail doors to convert consumer engagement into purchase.
Beyond the tournament itself, Nike is positioning football as a multi-year growth engine spanning footwear, apparel, and streetwear. The company is aiming to build a unified football marketplace that extends from on-pitch performance to street culture, sustaining demand beyond the World Cup cycle.
The analysts remain constructive on Nike's turnaround but cautioned that execution is uneven, with China, Europe, and direct-to-consumer still works in progress. A full earnings recovery is not expected before fiscal 2028.
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights.
We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of NIKE, Inc. (NYSE: NKE) breached their fiduciary duties to shareholders.
If you currently own NIKE stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Why Your Participation Matters:
Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
Did NIKE, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire
NEW YORK, June 5, 2026
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights.
We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of NIKE, Inc. (NYSE: NKE) breached their fiduciary duties to shareholders.
If you currently own NIKE stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Why Your Participation Matters:
Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060 [email protected] [email protected]
https://www.halpersadeh.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/did-nike-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302792984.html
SOURCE Halper Sadeh LLP
CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs. Insider Cluster Buys: Stocks that multiple company officers and directors have bought. Double Buys: Companies that both Gurus and Insiders are buying Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.
Key Takeaways NIKE sees early footwear stabilization with gains in running, basketball and global football.Newer performance franchises are expanding as NIKE reduces reliance on older classic styles.Inventory-clearing, discounting and competition persist, but sell-through trends are improving. NIKE Inc. (NKE - Free Report) is showing early signs of stabilization in its core footwear business following several quarters marked by inventory imbalances, elevated promotional activity and evolving consumer preferences. As the largest contributor to the company’s revenue base, footwear remains central to NIKE’s turnaround efforts. Recent management commentary suggests that the company is making progress in restoring marketplace health, improving product assortments and strengthening demand across key performance categories.
A notable sign of stabilization is the improving traction in strategic footwear segments such as running, basketball and global football. Management highlighted strong momentum in running and double-digit growth in football, reflecting positive consumer response to newer product offerings. At the same time, NIKE is intentionally reducing its dependence on older classic franchises and reallocating resources toward innovation-led platforms that can drive sustainable growth. This portfolio shift is aimed at improving product productivity while enhancing the overall quality of sales.
While encouraging signs are emerging, the recovery is far from complete. Footwear performance remains constrained by inventory-clearing efforts, elevated discounting and intense competition across key markets. Nevertheless, improving sell-through trends, stronger wholesale engagement and a more focused innovation pipeline indicate that the business may be moving toward a healthier footing. If NIKE can successfully balance inventory discipline with new product launches, its footwear segment could become a key catalyst for broader revenue and earnings stabilization.
Management’s focus on expanding newer performance franchises while reducing reliance on legacy styles should also support a healthier product mix. If these initiatives continue to gain traction, the footwear business could emerge from the current transition period with stronger growth and profitability prospects.
NKE’s Competition in the Global Arenaadidas AG (ADDYY - Free Report) and lululemon athletica inc. (LULU - Free Report) are NKE’s key competitors in the global market.
adidas is seeing encouraging signs of stability in its footwear business as strong demand for running, football and Originals continues to support growth across key markets. Management has emphasized product visibility, franchise strength and disciplined inventory management as drivers of healthier marketplace dynamics. Improved full-price sell-through and sustained consumer interest in both performance and lifestyle offerings suggest that adidas’ footwear segment is benefiting from stronger brand momentum and a more balanced product portfolio.
lululemon is steadily strengthening its footwear business through innovation and expansion across targeted categories. While footwear remains a smaller contributor compared with apparel, the company continues to broaden its product assortment and deepen consumer engagement through a premium, performance-focused approach. Supported by its loyal customer base, direct-to-consumer model and growing brand awareness, lululemon is positioning footwear as an important long-term growth opportunity while maintaining disciplined inventory and pricing strategies.
NKE’s Price Performance, Valuation & EstimatesShares of NIKE have lost 24% in the past three months compared with the industry’s decline of 18.9%.
Image Source: Zacks Investment Research
From a valuation standpoint, NKE trades at a forward 12-month price-to-earnings ratio of 23.03X compared with the industry’s average of 20.22X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for NKE’s fiscal 2026 earnings implies a year-over-year decline of 31%, while that for fiscal 2027 indicates growth of 24.3%. The company’s EPS estimates for fiscal 2026 and 2027 have been stable in the past 30 days.
Nike (NKE 2.24%) stock has really been suffering. The active-wear giant, which is the largest company of its kind by far, has seen its stock plummet 75% from its all-time high. Worse, it's still in the midst of figuring out how to turn around, so a stock rebound may still be far out on the horizon.
In general, it's a good idea to wait for progress before buying a turnaround stock. But Nike has something else going for it: an excellent dividend. Is that enough of a reason to buy it right now?
Nike x Melitta Baumeister Vomero Premium Pile. Image source: Nike.
The brand to beat in activewear Nike is one of the largest apparel companies in the world, and it's far ahead of the competition in the athletic wear space. Consider its revenue in comparison with Adidas, Lululemon Athletica, Under Armour, and On Holding.
NKE Revenue (TTM) data by YCharts
It has incredible brand power, and despite recent woes, it remains the No. 1 brand in both footwear and clothing in Piper Sandler's annual Taking Stock With Teens survey. That's an excellent indication of the company's future opportunity.
Can Nike withstand the competition? The cracks are starting to show, though. It used to have more sales than most of its competition combined, but that's not the case right now. Here's the arc of sales over the past five years.
NKE Revenue (TTM) data by YCharts
Newer companies like On are resonating with an upper-income clientele that's still spending under pressure, and older competitors, like Berkshire Hathaway's Brooks, developed an edge in the sport segment while Nike was focused on lifestyle and reliable franchises that turned out not to be so reliable.
New CEO Elliott Hill has crafted a strategy that's rooted in a return to sport and speed in innovation. Management also walked back its disastrous breakup with wholesalers, which was one of the ways competitors were able to reach more customers; without Nike products on the shelves, shoppers reached for alternatives.
Today's Change
(
-2.24
%) $
-1.03
Current Price
$
44.93
There have been several bright spots so far on the journey back. In the 2026 fiscal third quarter (ended Feb. 28), revenue was flat from last year instead of declining, and wholesale revenue increased 5%. The running category was up 20%, and the global football segment was also up double digits.
Is the dividend enough? While this is playing out, Nike continues to increase the dividend. And since yield moves conversely with stock price, the yield has climbed from around 1% historically to about 3.8% right now.
Nike is a blue chip dividend stock that has raised its dividend for 24 years, even under rough conditions. I do think that it's reliable enough for passive income investors to buy it today, and if you have a long time horizon, you also have the opportunity to see the stock rebound.
Jennifer Saibil has positions in On Holding. The Motley Fool has positions in and recommends Berkshire Hathaway, Lululemon Athletica Inc., Nike, and On Holding. The Motley Fool recommends Under Armour. The Motley Fool has a disclosure policy.
It is World Cup time, as the month-long soccer tournament kicks off June 11 throughout North America and lasts until July 19.
Perhaps no U.S. brand is tied to the "beautiful game" more than Nike (NKE 2.24%). While Nike is not an official sponsor of the FIFA World Cup, many of the sport's leading players, like Cristiano Ronaldo and Kylian Mbappé, have endorsement deals with Nike. Also, Nike provides the shoes and "kits" for 12 teams, including France, England, Brazil, the United States, Canada, and the Netherlands.
So, Nike will have a ton of visibility over the next month, not just from the players on the field, but on the airwaves and in social media through an advertising campaign it is launching for the World Cup.
Image source: Getty Images.
Rip the Script Rip the Script is Nike's new World Cup ad campaign, highlighted by a star-studded 6-minute film. It's designed to introduce the universe of Nike football -- the game, the players, the culture, and, of course, Nike shoes and apparel.
"We are also utilizing the World Cup as an opportunity to catalyze the football marketplace for quarters to come," CEO Elliott Hill said on the fiscal Q3 earnings call. "By the end of the tournament, we will have elevated our presentation in more than 5,000 football doors around the world, with wholesale partners and Nike Direct."
One of the major changes that Hill has ushered in since becoming CEO is renewing the focus on wholesale channels, like Dick's Sporting Goods, Foot Locker, Shoe Palace, and Academy Sports. Wholesale sales were up 5% in the last quarter, while direct sales were down 5% and overall sales were flat.
Hill said he expects to deepen the relationship with these wholesalers through the World Cup.
While Nike has some wholesale sales momentum, it is saddled with declining earnings. In the latest quarter, the third quarter of fiscal year 2026, which ended Feb. 28, expenses rose 2%, and cost of sales jumped 2% due in large part to tariffs. The higher tariffs have contributed to the 3% decline in gross profits and a 130-basis-point drop in gross margin to 40.2%. As a result, net income plummeted 35%.
CFO Matthew Friend said on the call that tariffs will be a headwind until Q2 of fiscal 2027, when mitigation efforts kick in. But the outlook is for a low-single-digit revenue decline through calendar year 2026, and continued margin pressure. By Q2 2027, the December quarter, Friend said the company anticipates margin expansion and the beginning of an earnings recovery.
Today's Change
(
-2.24
%) $
-1.03
Current Price
$
44.93
So is Nike a buy now, given the World Cup's visibility around the corner? The tournament may not have much immediate impact on sales, but the visibility could give the stock a lift, as could a solid Nike Q4 earnings release on June 30.
With shares down 31% year to date, the stock is trading at 22 times earnings, down considerably from earlier levels.
I think Nike stock may actually be nearing the buy zone.
Here's why: Investors have already baked in depressed near-term sales and margins, so a decent earnings report, an expected earnings recovery in fiscal 2027, the visibility of the World Cup, and a reasonable valuation might just make Nike a buy heading into the World Cup.
HomeIndustriesRetail/WholesaleThe Ratings GameThe Ratings GameRBC’s 12-month target for Nike shares knocked down to $50 from $70Last Updated: June 10, 2026 at 4:58 p.m. ET
First Published: June 10, 2026 at 7:48 a.m. ET
Nike’s stock suffered a crunching tackle on the eve of the World Cup as RBC Capital Markets brought its share-price target for the athletic-apparel giant down from $70 to $50 on slower revenue growth than previously foreseen.
Shares of Nike NKE fell 1.5% to $43.96 on Wednesday, and the stock is down by more than 30% in the past six months. It comes a day before the World Cup begins and as shares of its rival and official partner of the soccer tournament, Adidas XE:ADS ADDYY, have risen about 4% in the same span.
England is one of the nations with jerseys provided via Nike. (Photo by Eddie Keogh - The FA/The FA via Getty Images)
The FA via Getty Images
With the 2026 FIFA World Cup imminent, sportswear giants are preparing for what should be one of the most lucrative merchandise events in soccer’s history and a global showcase for new national team kits from Nike, Adidas and Puma.
But there is a growing challenge that could disrupt the traditional playbook for tournament merchandise sales as fans increasingly turn to retro shirts.
Demand for vintage and second-hand soccer shirts has exploded. What was once a niche collectors’ market has become a mainstream fashion category, fueled by social media, sustainability, nostalgia and a younger generation that views jerseys as lifestyle apparel rather than simply sports merchandise.
The result is that many supporters arriving at World Cup matches in 2026 or watching from home may be wearing shirts from previous tournaments rather than the latest official releases.
Vintage jerseys from the 1980s, 1990s and early 2000s now command premium prices on resale platforms. Shirts associated with iconic moments — such as Argentina's 1986 World Cup triumph, Brazil's 1998 campaign, England's Italia '90 run or France's 1998 victory — have become highly sought-after collectibles.
The market has been helped by the emergence of specialist retailers such as Classic Football Shirts, which has transformed soccer-shirt collecting into a global business. The company now ships jerseys worldwide and has collaborated directly with clubs, brands and players.
Gen X And Gen Z Love The 1990sOnline marketplaces including eBay, Depop and Vinted have further democratized the market, making rare shirts accessible to a broader audience. At the same time, soccer shirts have become increasingly visible in mainstream fashion. Celebrities, musicians and influencers regularly wear vintage jerseys in social media posts, while luxury brands have incorporated football-inspired designs.
MORE FOR YOU
And for younger consumers, a retro shirt often carries more cultural value than the latest official release. Many fans attending matches in Los Angeles, New York, Dallas and Miami will likely wear vintage jerseys from the 1994 tournament in the U.S. Shirts worn by the United States, Mexico, Germany and Nigeria during the 1990s are already among the most searched-for items on resale platforms.
“We seem to be in a 30-year fashion cycle at the moment, meaning the 1990s are especially popular for retro jerseys, and lots of the current kits are reflecting that and tapping into that nostalgia. Other kits, like Mexico’s, also play on the country’s heritage,” EY Global Consumer Senior Analyst Jon Copestake said.
“What we are seeing is much more of a blending of kits and streetwear, so the jersey becomes the central piece for the streetwear merchandise, which has also been expanded to have far more aparel for women as the popularity of the game has picked up hugely among females. These designs again often reflect nostalgia but also connect with newer generations through collaborations with social media influencers, musicians and so on,” he added.
Brands Leverage Streetwear CrossoverOne company leveraging the intersection of football culture and streetwear, the U.K.’s Corteiz launched its Rules The World Cup Tour collection of soccer-inspired jerseys and tracksuits representing 11 nations, from England and France to Ghana, Mexico and the U.S. with an ambitious six-week, 11-city global tour.
Meanwhile, Fanatics, the official retail partner for England, opened a pop-up England store on London’s famous Carnaby Street on 21 May featuring England kits, merchandise and limited-edition releases throughout much of the tournament.
Retro shirts from the 1994 torunament are expected to be among those in highest demand. (AP-Photo/str/Thomas Kienzle)
Copyright 1994 AP. All rights reserved.
Sportswear companies are not standing still. Adidas has enjoyed considerable success with retro-inspired collections, including reissues of classic national team apparel and heritage-focused ranges. Several recent launches have intentionally referenced iconic designs from previous decades.
Nike has adopted similar strategies, drawing on historic aesthetics and archival logos to create products that blend nostalgia with modern performance technology. Puma has also expanded its lifestyle and heritage offerings, recognizing that consumers increasingly buy football apparel for everyday wear.
World Cup Key For BrandsThe tournament arrives at a pivotal moment. Adidas continues to enjoy strong momentum, posting 7% revenue growth in the first quarter, while Nike is working to reignite growth after reporting flat revenues.
Adidas has leaned heavily into football heritage through its Backyard Legends campaign, a cinematic short film featuring actor Timothée Chalamet alongside stars including Lamine Yamal, Jude Bellingham and Trinity Rodman. The campaign celebrates football culture through a blend of nostalgia, street football and sporting icons including David Beckham, Zinedine Zidane and Lionel Messi.
The campaign has been supported by retro national team jersey reissues, a Bad Bunny footwear collaboration and a range of digital activations designed to deepen fan engagement.
"Everyone remembers that feeling: playing for the joy of it, no pressure, no expectations," said Florian Alt, VP of global brand communications at Adidas.
Nike, meanwhile, has opted for a six-minute Rip the Script film which sees stars including Kylian Mbappé and Vinícius Júnior reject the conventions of traditional football advertising, creating a fast-paced narrative packed with celebrity cameos and cultural references.
“We didn’t want to follow the traditional marketing playbook,” Helena Thornton, VP of Nike global brand management said. "We wanted to give them something worth talking about, worth clipping, worth wearing, worth showing up to."
The lesson is clear: if fans want vintage, brands may need to lean into that desire for authenticity according to Copestake.
“Immediately ahead of the tournament, a lot of the headlines have been negative, from high ticket prices to soft hotel demand and then also the challenges around people arriving in the U.S. But once the tournament begins, it’s likely that the games will takeover the attention. In 1994 there was an expectation that the tournament would not be a success, but actually the U.S. embraced it,” he noted.
“The U.S. is such a huge retail market that the success of otherwise of this World Cup is unlikely to have a huge long-term impact, but the locations that stand to gain most are some of the smaller city venues like Dallas, Philadelphia and Kansas City, where many retailers and F&B outlets should see a positive impact,” he said. “Mexico and Canada are likely to see a more direct commercial boost and both are seeing it as an opportunity to showcase their countries.”
Stock futures slipped Wednesday morning as investors weighed renewed geopolitical tensions and fresh inflation data. Dow futures are off by triple digits, while S&P 500 and Nasdaq-100 futures are also pointed firmly lower, after President Donald Trump warned Iran that negotiations were taking “too long” and hinted at further action. Oil prices moved up 2% in response. Meanwhile, May’s core consumer price index rose 0.2% month over month, below economists’ 0.3% forecast, while the annual rate held steady at 2.9%, helping futures recover from earlier lows.
Continue reading for more on today's market, including:
This 2% SPX selloff may be different according to Senior Quantitative Analyst Rocky White. Historical pullback signaling Vertiv stock upside. Plus, SMCI sinks on stock sale, retailer jumping off Q3 report, and Nike continues spiraling.
5 Things You Need to Know Today The Cboe Options Exchange saw more than 9.3 million call contracts and 9 million put contracts traded on Tuesday. The single-session equity put/call ratio fell to 0.96, while the 21-day moving average rose to 0.59. Super Micro Computer (NASDAQ:SMCI) shares are down 12% premarket, after the tech hardware company announced it plans to raise $7 billion in stock-related deals to help cover hardware costs. SMCI stock is continuing the downtrend that began after a rejection at $50 earlier this month. Year-to-date, the stock is up 38% heading into today. Beloved country-themed restaurant chain Cracker Barrel (NYSE:CBRL) gained 11% before the bell after scoring a bottom-line beat for its fiscal third quarter, hiking its full-year revenue, and adjusting EBITDA guidance. CBRL is poised to open at a multi-month high. Nike (NYSE:NKE) is down 2% ahead of today's open, reeling from a RBC downgrade to "sector perform" from "outperform," with notes of Nike's weak turnaround. Heading into today, Nike stock is still near eight-year lows and carries a 30% nine-month deficit. investors will be eyeing key financial reports later this week.
Semiconductor Slide Hits Asia Asian markets moved lower on Wednesday as semiconductor stocks resumed their slide. The South Korean Kospi staged another big swing with a 4.5% loss, while Japan’s Nikkei dipped 1.9%, Hong Kong’s Hang Seng shed 0.6%, and China’s Shanghai Composite lost 0.4%.
European markets are broadly in the red as well. London’s FTSE 100 was last seen down 0.6%, while the French CAC 40 and German DAX drop 0.7% and 1.1%, respectively. Meanwhile, the DIW economic institute said Germany was likely to slip into a technical recession this year due to the war in Iran.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Considering buying NUVL stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Nike (NKE, Financials) is still working through a difficult reset, and RBC Capital says investors may need to wait longer for a clear recovery.
The firm downgraded Nike to Sector Perform from Outperform and lowered its price target to $50, citing slower-than-expected progress under CEO Elliott Hill.
RBC said Nike still has work to do on product design, pricing and brand momentum. The analysts also pointed to stronger competition from Hoka, On Running, New Balance, Lululemon, Vuori and Alo Yoga.
The concern is simple: Nike remains a powerful brand, but legacy alone may not be enough in a more crowded sportswear market.
For investors, 2026 may still be a transition year. RBC expects limited revenue growth as Nike cleans up older business issues and tries to rebuild demand with newer products.
Nike (NKE - Free Report) closed at $44.93 in the latest trading session, marking a -2.24% move from the prior day. This move lagged the S&P 500's daily gain of 0.5%. Elsewhere, the Dow saw an upswing of 0.7%, while the tech-heavy Nasdaq appreciated by 0.31%.
Shares of the athletic apparel maker have appreciated by 9.38% over the course of the past month, outperforming the Consumer Discretionary sector's gain of 1.82%, and the S&P 500's loss of 0.23%.
The upcoming earnings release of Nike will be of great interest to investors. The company's earnings report is expected on June 30, 2026. The company's upcoming EPS is projected at $0.11, signifying a 21.43% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $10.87 billion, down 2.03% from the year-ago period.
NKE's full-year Zacks Consensus Estimates are calling for earnings of $1.49 per share and revenue of $46.36 billion. These results would represent year-over-year changes of -31.02% and +0.11%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Nike. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 1.67% fall in the Zacks Consensus EPS estimate. Nike presently features a Zacks Rank of #4 (Sell).
Looking at valuation, Nike is presently trading at a Forward P/E ratio of 24.83. This signifies a premium in comparison to the average Forward P/E of 16.01 for its industry.
We can also see that NKE currently has a PEG ratio of 1.99. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. NKE's industry had an average PEG ratio of 1.93 as of yesterday's close.
The Shoes and Retail Apparel industry is part of the Consumer Discretionary sector. At present, this industry carries a Zacks Industry Rank of 94, placing it within the top 39% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
NASDAQ | TSX: ACB The Globe and Mail's Report on Business Women Lead Here List acknowledges Aurora's commitment to inclusive leadership at the executive level EDMONTON, AB, March 30, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian‑based leading global medical cannabis company, has been named on The Globe and Mail's 2026 Report on Business Women Lead Here list for the second consecutive year. The annual editorial benchmark recognizes publicly traded Canadian companies demonstrating strong executive‑level gender diversity, underscoring Aurora's continued commitment to inclusive leadership.
Key Takeaways ACB shares are down 19% YTD, underperforming the cannabis industry's 15% decline.Aurora Cannabis is leaning on medical cannabis, with revenues up ~20% to C$211.5M in nine months.Aurora Cannabis is scaling back consumer cannabis amid pricing pressure and intensifying competition. Shares of Aurora Cannabis (ACB - Free Report) have lost 19% year to date compared with the industry‘s 15% decline, as shown in the chart below.
Image Source: Zacks Investment Research
The underperformance reflects a mix of sector-wide pressures and company-specific positioning. While intensifying competition in Canada’s mature cannabis market continues to weigh on Aurora Cannabis’ growth prospects, its limited presence in the United States has also constrained its ability to capitalize on recent cannabis-related policy momentum.
Let’s delve into the company’s fundamentals to better assess the stock following the decline.
Medical Cannabis Remains Aurora Cannabis’ Core Growth EngineAurora Cannabis continues to anchor its growth strategy around global medical cannabis, which remains the primary driver of both revenue and profitability. The segment has delivered consistent momentum, supported by strong demand across key international markets and a disciplined focus on higher-margin products.
For the nine months of fiscal 2026 (year ended March 2026), medical cannabis revenues increased about 20% year over year to C$211.5 million, accounting for nearly 75% of total sales. Growth was driven by increasing contributions from international markets, such as Germany, Australia and Poland, alongside steady demand in Canada from both insurance-covered and self-paying patients.
The strength of this segment is also evident in its margin profile. Higher-margin international sales, favorable product mix and ongoing production efficiencies have supported margin expansion through most of the fiscal year, with profitability levels stabilizing in the most recent quarter. This has translated into meaningful operating leverage, with adjusted EBITDA rising 35% year over year to about C$45 million for the nine months ended December 2025.
Aurora Cannabis’ latest updates further reinforce this trajectory. Management continues to prioritize international medical markets, where regulatory frameworks, pricing stability and demand visibility are more favorable compared to the recreational segment. The company is actively aligning its operations and capital allocation toward these markets, while streamlining lower-return activities to enhance overall profitability.
Aurora Cannabis expects global medical cannabis to remain its primary growth engine. The company expects fiscal 2026 medical cannabis revenues to be in the range of C$269-C$281 million, representing 10-15% year-over-year growth, supported by continued international expansion, new product launches and scaling in key European markets. Adjusted EBITDA is expected to reach C$52-C$57 million, with the company maintaining positive free cash flow as efficiencies improve.
ACB’s Consumer Cannabis Takes a Back SeatAurora Cannabis’ consumer cannabis business continues to weaken, reflecting structural challenges in Canada’s oversupplied adult-use market. Persistent price compression and aggressive competition have eroded both revenue potential and margins, making the segment increasingly unattractive relative to the company’s medical operations.
As a result, Aurora is now actively repositioning away from this segment. The company is scaling back participation in lower-margin consumer markets in Canada and redirecting capital and operational focus toward its higher-margin global medical cannabis platform. This shift highlights ACB’s effort to prioritize segments with stronger pricing power, more predictable demand and better long-term returns.
The strategic pullback is also expected to streamline Aurora’s cost structure. Management has indicated that reducing exposure to consumer cannabis should lower sales and marketing expenses and support consolidated margin expansion over time. However, the transition is not without near-term friction, with one-time costs expected to impact cash flow in the fourth quarter of fiscal 2026.
Intensifying CompetitionAurora Cannabis operates in an increasingly competitive global cannabis market, facing established players, such as Curaleaf Holdings and Tilray Brands (TLRY - Free Report) . With most Canadian and international cannabis producers targeting a limited set of high-growth markets, competitive intensity remains elevated and could constrain ACB’s ability to sustain outsized market share gains.
This pressure is particularly pronounced in international markets, such as Europe, where Aurora Cannabis is focusing on its expansion strategy. Peers like Curaleaf and Tilray are also scaling their presence in these regions, increasing competition in the very markets expected to drive the company’s future growth. As a result, while international expansion offers meaningful opportunities, it also introduces execution risk and may limit pricing power over time.
ACB Valuation EstimatesEstimate movements for fiscal 2026 and 2027 have remained unchanged over the past 60 days.
Image Source: Zacks Investment Research
How to Play ACB Stock?Aurora Cannabis has made meaningful progress in repositioning its business, with medical cannabis emerging as a key growth driver and profitability improving. The company’s expanding footprint in international markets provides a pathway to offset structural challenges in Canada’s mature recreational market.
However, the investment case remains balanced. Persistent pricing pressure, ongoing weakness in the consumer cannabis segment and restructuring-related costs continue to weigh on near-term visibility. At the same time, rising competition in international markets could limit Aurora’s ability to fully capitalize on its medical cannabis momentum. Consistent earnings estimates suggest that the recent strategic progress is not yet translating into upward revisions, indicating limited near-term upside potential.
ACB currently carries a Zacks Rank #3 (Hold), which suggests that investors may be better off waiting for clearer signs of sustained earnings growth or improved industry conditions before building meaningful positions.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
, /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce it has acquired Safari Flower Company, an established EU GMP certified cannabis cultivator and manufacturer. Aggregate consideration is valued at $26.5 million, subject to customary adjustments, and inclusive of a cash payment of $2 million that is contingent on satisfaction of certain conditions (the "Transaction").
"The acquisition of Safari Flower Company marks an important milestone for Aurora as we continue to purposefully invest in expanding our EU GMP capacity to support the rapidly growing international medical cannabis market. We intend to leverage our extensive plant science and operational expertise to increase the supply of high quality, EU GMP manufactured flower that further enhances our leadership in these expanding, high margin and highly regulated markets. An enhanced supply chain will enable us to capture greater international market share while delivering superior quality and value to our most respected patients worldwide," said Miguel Martin, Executive Chairman and Chief Executive Officer for Aurora.
Strategic Rationale
Safari Flower Company's 59,000 square foot, purpose-built EU GMP certified indoor cultivation and manufacturing facility in Ontario, Canada will provide the Company with incremental capacity that is closely aligned with its existing cultivation and manufacturing sites. The increased capacity will be used to supply EU GMP flower to Aurora's key international markets, including Germany, Australia, Poland, and the UK, and support further market expansion. This transaction is expected to deliver positive Adjusted EBITDA contributions in fiscal year 2027, with incremental benefits in fiscal year 2028 and beyond as these assets are optimised within the Company's supply network. Aurora intends to leverage its plant science and operational expertise to realize operational efficiencies, improve cultivation yields and support commercial execution in the high margin international markets. Transaction Details
Aurora, through a wholly-owned subsidiary, indirectly purchased 100% of the shares of 9869247 Canada Limited ("Safari Flower Company") for aggregate consideration valued at $26.5 million, inclusive of a cash payment of $2 million that is contingent on satisfaction of certain conditions. As consideration on closing, Aurora (i) issued the selling shareholder 2,417,180 common shares; and (ii) paid the selling shareholder $15 million in cash, subject to customary adjustments post-closing.
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include statements regarding the Transaction, including, but not limited to: the impact of the Transaction on the Company's financial performance and the synergies, revenue, positive cash flow and positive Adjusted EBITDA expected to be realized as a result of the Transaction.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, current and expected market trends, product supply and demand, financial performance, and ongoing global regulatory developments, as well as publicly available information from governmental sources, market research and industry , and assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
Non-GAAP Measures
This news release contains reference to certain financial performance measures that are not recognized or defined under IFRS (termed "Non-GAAP Measures"). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Non-GAAP Measures in this news release include, but are not limited to, Adjusted EBITDA. Non-GAAP Measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company's operating results, underlying performance and prospects in a manner similar to Aurora's management. Accordingly, these non-GAAP Measures are intended to provide additional information and to assist management and investors in assessing financial performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The information included under the heading "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" in the Company's management's discussion and analysis for the three and nine months ended December 31, 3025, and 2025 (the "MD&A") is incorporated by reference into this news release. The MD&A is available on the Company's issuer profile on SEDAR+ at www.sedarplus.com.
Markets don’t usually wait for permission — they anticipate it. That’s why cannabis stocks jumped ahead of the official news that the Justice Dept. would reclassify marijuana from Schedule I to Schedule III. But here’s the real question investors should be asking: does this long-awaited shift actually change the investment case, or just the headlines?
Let’s dig into what this move means — and what it doesn’t.
A Long-Awaited Shift — and a Quick Reality Check The DOJ officially moved marijuana to Schedule III, placing it alongside drugs like ketamine and certain steroids instead of heroin or LSD. That’s not legalization — but it’s a meaningful policy shift.
The market reaction came fast:
Tilray Brands (NASDAQ:TLRY) rose 14% yessterday Canopy Growth (NASDAQ:CGC) climbed 21% Aurora Cannabis (NASDAQ:ACB) was up a more muted 6.7% All three stocks are lower in midday trading, down mid- to high-single-digits That pullback tells you something important: traders were positioned early and are now taking profits. Step back further, and the longer-term picture looks less encouraging:
Company
Decline from 52-Week High
Tilray
-67%
Canopy Growth
-46%
Aurora Cannabis
-48%
That’s not a sector riding a wave of sustained momentum. It’s one still trying to find its footing.
What Schedule III Actually Changes Let’s strip away the jargon. Reclassification doesn’t legalize marijuana federally — states still operate under a patchwork of laws. But it does remove one major obstacle: IRS Code Section 280E. That means cannabis companies could now deduct ordinary business expenses.
Here’s why that matters:
Under Schedule I, companies couldn’t deduct payroll, rent, or marketing Effective tax rates often exceeded 60% to 70%, based on company filings and IRS guidance Moving to Schedule III allows normal corporate tax treatment — typically 21% federally That’s a direct hit to the bottom line — and a positive one.It also improves access to banking services (fewer restrictions for lenders), credit markets (lower borrowing costs), and Institutional capital (previously sidelined investors may step in)
Tilray, for example, reported in its latest earnings release that it generated $188 million in quarterly revenue, but profitability has remained inconsistent. Lower taxes could help — but only if core operations improve.
Canopy Growth, meanwhile, reported $78.5 million Canadian ($53.5 million) in quarterly revenue in its most recent filing, with continued net losses. Tax relief helps — but it doesn’t fix declining sales.
Reclassification vs. Legalization Is Still a Big Gap Here’s where expectations and reality diverge. Investors have been waiting years for a breakthrough moment. This feels like one — but it’s not the finish line. Surprisingly, state-level legalization hasn’t delivered the growth many expected:
California’s legal cannabis market saw sales decline 11% year over year in 2025, its third consecutive year of decline Price compression from oversupply continues to pressure margins across multiple states Canada offers another cautionary tale. After full federal legalization in 2018, Canopy Growth and peers faced regulatory bottlenecks and high excise taxes, many producers struggled with inventory write-downs and excess capacity, while profitability has remained elusive years later. In other words, legalization didn’t eliminate business challenges — it exposed them.
Reclassification is an even smaller step.It removes friction, but doesn’t create demand.
Key Takeaway In short, this is progress. Real progress. Lower taxes, better banking access, and reduced stigma all help the industry mature.
But investing isn’t about headlines — it’s about outcomes. Here’s what the numbers and trends tell us:
Cannabis companies still struggle with profitability and pricing pressure Revenue growth has flattened or declined in key markets Stocks like Tilray Brands, Canopy Growth, and Aurora Cannabis remain far below their highs — 67%, 46%, and 48%, respectively Granted, lower taxes could improve margins. That said, margins only matter if there’s sustainable demand and disciplined supply. Reclassification is a necessary step. It is not a sufficient one. For investors, that distinction matters.
When all is said and done, cannabis remains a story of potential — not proven performance. Until these companies show consistent revenue growth, positive free cash flow, and pricing power, sharp investors should treat rallies like this as trading opportunities, not long-term entry points.
Aurora Cannabis Inc. has transformed into a cannabis-focused company with improving international revenue and margins, while spinning off its Bevo division. ACB's balance sheet now shows net cash of C$46.7 million, achieved through equity sales, and enterprise value trades at just 3.8x projected FY27 adjusted EBITDA. I target a 64% upside for ACB to US$5.58 within a year, based on a 6x FY28 adjusted EBITDA multiple, with the stock trading below tangible book value.
Q1 launches reinforce Aurora's medical‑first strategy, expanding access to high‑quality products across multiple formats Scaled launches across Canada, Europe and Australia support growing demand in regulated international medical markets Continued focus on quality, patient needs and reliable global supply through Aurora's extensive GMP‑certified network , /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian‑based leading global medical cannabis company, is significantly expanding its global medical cannabis portfolio, with new product launches rolling out across Canada, Europe and Australia. The company continues to shape the global cannabis landscape by introducing new products and formats around the world. The newly expanded lineup includes dried flower, pre‑rolls and pastilles, reflecting Aurora's long‑standing focus on innovation, quality and patient choice, while driving sustainable growth internationally.
Aurora's global medical cannabis portfolio expansion. (CNW Group/Aurora Cannabis Inc.) "As our global medical business continues to grow, our focus remains on delivering consistency and reliability across the markets we serve," says Lana Culley, VP Innovation & International Operations at Aurora. "By expanding our offerings in key countries, we're responding to clear patient and prescriber demand with products that meet local regulatory standards, offer meaningful choice across formats, and can be supplied reliably at scale - all while reinforcing the level of quality and trust expected from us."
The new products align with Aurora's medical‑first strategy and leverage the company's global GMP‑certified manufacturing network.
Aurora's expanded medical cannabis offerings will roll out in their respective markets between now and June; new product launches include:
Germany – A broader portfolio of medical cannabis options
San Raf® – Pink OG KushTM | Indica, Dried Flower, THC 25-27%, CBD <1.0%. This cultivar has a spicy and sweet aroma profile of lemon, lavender, spice and is bred from OG Kush Daily SpecialTM – Lemon SorbetTM | Sativa, Dried Flower, THC 21%, CBD <1.0%. This cultivar has an aroma profile of spice, wood, lemon and is bred from Gelonade X Biscotti Poland – Expanded potency range across existing offerings
Cannabis flos Aurora - Electric HoneydewTM | Hybrid, Dried Flower, THC 27%, CBD ≤1.0%. This cultivar has an aroma profile of melon, gas, pine and is bred from Girl Scout Cookies x 91 OG Krypt Melon Cannabis flos Aurora – ChemangoTM Kush | Indica, Dried Flower, THC 29%, CBD ≤1.0%. This cultivar has an aroma profile of fruity, sour, chem and is bred from OG Kush x Wedding Cake x GMO x Fuel Australia – Featuring pastilles, an edible format that is discreet, precisely dosed, and long-lasting
WMMCTM - Seasonal StashTM Dank MatterTM | Sativa, Dried Flower, 28g, THC 24-30%. This cultivar has an aroma profile of gas, licorice, vanilla, and is bred from Banana Puddintain x White Mac WMMCTM - Seasonal StashTM Custard KushTM | Indica, Dried Flower, 28g, THC 25-31%. This cultivar has an aroma profile of creamy, berry, oak, and is bred from La Bomba x White Mac San Raf® – Melon MouthTM | Hybrid, Pre-roll, 7x0.5g, THC 22-28%. This cultivar has an aroma profile of fruity, sweet, diesel and is bred from Girl Scout Cookies x Chem 91 x Crypt OG San Raf® – Stink BiscuitTM | Indica, Dried Flower, 3.5g, THC 22-28%. This cultivar has an aroma profile of gas, funk, sourdough and is bred from GMO x Animal Cookies Together, these launches reflect Aurora's continued role in advancing regulated medical cannabis globally, supporting the growth of these markets with high‑quality products, diverse formats, and reliable supply.
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding new product launches across Aurora's key international markets, expectations for growing medical demand in regulated international markets, and the Company's continued focus on quality, patient needs and reliable global supply through Aurora's extensive GMP‑certified network.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, current and expected market trends, product supply and demand, financial performance, and ongoing global regulatory developments, as well as publicly available information from governmental sources, market research and industry, and assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
Canadian grant protects Aurora‑developed genetics bred through the company's advanced research and breeding program
, /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announced today it has been granted Plant Breeders' Rights in Canada for two proprietary cannabis cultivars developed through its world-class breeding program. This certification gives Aurora the exclusive rights to grow, propagate, and sell finished products produced from these varieties.
Canadian grant protects Aurora‑developed genetics bred through the company’s advanced research and breeding program (CNW Group/Aurora Cannabis Inc.) The two protected cultivars, SOT20R07-007 (known as Farm Gas™) and SOT20R07-005 (known as Driftwood Diesel™), were developed at Aurora Coast, Aurora's industry-leading research and development facility in Comox, British Columbia. The company carefully selected these cultivars based on their unique characteristics, including how well they grow and how consistently they perform. Farm GasTM and Driftwood DieselTM are core medical cannabis products available to patients in Germany, Poland, UK, Canada, and Australia.
"These plant breeders' rights recognize the depth of work behind our leading breeding, genetic development and testing program," says Lana Culley, Vice President, Innovation and International Operations at Aurora. "They reflect a disciplined, science‑driven approach to developing cultivars that deliver consistency, performance and reliability for medical cannabis patients around the world."
Understanding Plant Breeders' Rights in Canada
Plant Breeders' Rights are a form of intellectual property protection, similar to patents, that apply specifically to new and distinct plant varieties In Canada, plant breeders' rights are granted by the Canadian Food Inspection Agency (CFIA) and give breeders exclusive rights to produce and sell a protected plant variety This framework recognizes the significant scientific investment required to develop cultivars that are clearly different and produce the same results over time For Aurora, plant breeders' rights protect proprietary cannabis genetics developed through its internal breeding program, supporting continued innovation and long‑term research Aurora's robust genetics platform underpins its global medical cannabis leadership and supports the company's ability to develop differentiated premium products with consistent and reliable attributes. The protection of these varieties, as well as the recent grants received for select variety protection in Europe, enhances Aurora's competitive position globally.
Further details regarding Plant Breeders' Rights, can be found at https://inspection.canada.ca/en/plant-health/plant-varieties/plant-breeders-rights
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Plant Breeders' Rights granted by the CFIA to the Company in Canada and the associated benefits and advantages for the Company, as well as statements regarding the enhancement of Aurora's competitive position globally.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
, /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2026 on Thursday, June 11, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter and fiscal year 2026 before the opening of markets that same day.
Conference Call Details
Aurora Cannabis to host fourth quarter and fiscal year 2026 investor conference call DATE:
Thursday, June 11, 2026
TIME:
8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time
WEBCAST:
Click Here
Miguel Martin, Executive Chairman and Chief Executive Officer, and Simona King, Chief Financial Officer, will host the conference call and question and answer period. This weblink has also been posted to the Company's "Investor Info" link at https://www.auroramj.com/investors/ under "Events".
About Aurora Cannabis
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Statements
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the timing for the release of the Company's fourth quarter and fiscal year 2026 financial statements and the conference call to discuss the results.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
From global leadership to local impact, Aurora continues to support Veteran-focused programs across Canada, addressing food security, mental health, and community engagement
, /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, shares recent contributions through its Strains for Heroes program, expanding support for Veteran communities across Canada. Aurora's ongoing commitment to support Veterans includes five per cent of net profits from the sale of Strains for Heroes products being donated annually to veteran-focused organizations, up to a maximum of C$200,000. Aurora's latest contributions reflect a broader approach to care; supporting programs that address food security, mental health awareness, leadership development and community connection.
Aurora deepens its impact for Veterans across Canada. "At a time when support matters most, we remain committed to showing up for Veterans in ways that matter," said Geoff Hoover, SVP, Commercial Canada at Aurora. "That starts with listening, understanding what Veterans need today, and engaging with them directly to support the work being done in Veteran communities across the country. As a medical cannabis company, we also have a responsibility to ensure our Veteran programs support the real experiences of Veteran patients. We're proud to stand alongside these organizations making a difference."
Aurora's latest contributions support a range of Veteran-led organizations addressing real and immediate needs. Recent support includes a donation to the Veteran Association Food Bank to help distribute food assortments to Veteran families, as well as support for initiatives such as the Captain Nichola Goddard Fund which helps servicewomen, female Veterans, and their families access critical services. Donations were also made to national mental health awareness efforts like Sach in Motion and Sea to Sea for PTSD, where funds raised go towards treatment and education programs. Together, these contributions reflect Aurora's continued commitment to standing alongside Veterans and supporting the programs they rely on.
Built in collaboration with Veteran patients, Strains for Heroes helps guide the development of select medical cannabis products. Launched in 2022, the program reflects the company's approach to giving back, supporting Veteran organizations through ongoing contributions that help sustain their essential services, strengthen their operations, and expand the support they're able to provide to Veterans and their families across Canada.
Aurora is proud to support a growing number of veteran-focused organizations, by participating in community outreach, making charitable donations and amplifying their voices. Some partners include, Highway for Heroes, Quilts of Valour Canada, True Patriot Love, Fire Team K-9, and Veterans Association.
For more information about the Strains for Heroes product offerings and Aurora's veteran program, visit AuroraMedical.com.
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's ongoing contributions through its Strains for Heroes program, and associated impact including the expansion of support for veteran communities across Canada.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
Achieves Record Annual Global Medical Cannabis Net Revenue1 of $288.6 million, representing 18% YoY growth Delivers Record Annual Adjusted EBITDA1 of $53.8 million, representing 32% YoY growth Completes Accretive Acquisition of Safari Flower Company in April, an established EU-GMP Manufacturer, adding Critical Capacity to Serve Growing Profitable International Markets Maintains Strong Balance Sheet with ~$164.7 million of Cash, Short Term Investments and Cash Equivalents2 with no Debt , /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2026 periods ending March 31, 2026.
FY26 Q4 EARNINGS RESULTS "During fiscal year 2026, we exceeded our projection for global medical cannabis net revenue1 led by double-digit growth in Europe and delivered on our expectation for Adjusted EBITDA1 with both at record outcomes. Our performance validates Aurora's global medical cannabis strategy which has positioned us as a leading provider in Canada, Europe, Australia, and New Zealand," said Executive Chairman and Chief Executive Officer for Aurora, Miguel Martin.
"We believe Aurora's leadership in medical cannabis is built upon our regulatory expertise, extensive and recently expanded supply network of EU-GMP certified facilities, and proven commercial execution. We are confident that these attributes create a competitive advantage as we navigate the evolving industry dynamics to maintain and expand global market share, while driving international growth," concluded Mr. Martin.
[1] This news release includes certain non-GAAP financial measures, which are intended to supplement, not substitute for, comparable GAAP financial measures. See "Non-GAAP Measures" below for reconciliations of non-GAAP financial measures to GAAP financial measures.
[2] Cash Equivalents refers to cash, restricted cash and cash equivalents.
Fourth Quarter 2026 Highlights
(Unless otherwise stated, comparisons are made between fiscal Q4 2026 and Q4 2025 results and are in Canadian dollars and reflects only the results of continuing operations, unless otherwise noted.
On February 17, 2026, the Company completed the divestiture of its 50.1% ownership interest in Bevo Agtech Inc. ("Bevo"). As such, Bevo has been excluded from the Company's Q4 2026 continuing results, along with comparative figures, due to its classification as a discontinued operation.)
Consolidated Revenue and Adjusted Gross Profit:
Total net revenue1 was $84.8 million, as compared to $76.8 million in the prior year period. The 10% increase from the prior year period was mainly due to 14% growth in our global medical cannabis business and higher wholesale bulk cannabis net revenue, offset by lower quarterly net revenue1 in our consumer cannabis business.
Consolidated adjusted gross margin before fair value adjustments1 was 60% in Q4 2026 and 65% in the prior year period. Adjusted gross profit before FV adjustments1 was $50.5 million in Q4 2026 compared to $50.2 million in the prior year period.
Medical Cannabis:
Medical cannabis net revenue1 was $77.1 million, a 14% increase from the prior year period, delivering 91% of Aurora's Q4 2026 consolidated net revenue1 and 101% of adjusted gross profit before fair value adjustments1.
The increase in medical cannabis net revenue1 of $9.3 million was primarily due to higher sales in Germany, related to increased market size, and growth in Poland, along with higher revenue in Canada to insured patients related to broader portfolio offerings.
Adjusted gross margin before fair value adjustments1 on medical cannabis net revenue1 was 66% for the three months ended March 31, 2026, compared to 71% in the prior year period. The year-over-year decrease was due to higher sales with lower margins and strategic price reductions.
Consumer Cannabis:
Aurora's consumer cannabis net revenue1 was $3.6 million, compared to $8.2 million in the prior year period. The decrease was due to our strategic shift to focus on Canadian and international medical cannabis and wind down our consumer business.
Adjusted gross margin before fair value adjustments1 on consumer cannabis net revenue1 was 22%, a decrease from 27% compared to the prior year period. The decrease is primarily due to higher input costs related to third-party sourcing.
Adjusted Selling, General and Administrative ("Adjusted SG&A"):
Adjusted SG&A1 was $40.3 million for the three months ended March 31, 2026, compared to $35.4 million in the prior year period. The increase compared to the prior year period relates to increased headcount, higher contract labour in Europe and Australia, an expected credit loss of $1.9 million due to the insolvency of two customers and additional professional fees relating to public company costs incurred in the fourth quarter of the fiscal year.
Net Income (Loss):
Net loss from continuing operations for the three months ended March 31, 2026 was $27.6 million compared to a net loss of $12.1 million for the prior year period. The increase in net loss from continuing operations of $15.4 million was primarily related to other expenses of $1.7 million in the current period, compared to other income of $11.9 million in the prior year period. This was slightly offset by an increase in gross profit of $2.5 million.
Adjusted Net Income:
Adjusted net income1 was $5.6 million for the three months ended March 31, 2026 compared to $15.3 million for the prior year period. The $9.7 million decrease primarily relates to an increase in adjusted SG&A of $4.9 million, a decrease in foreign exchange gains and interest income, of $10.3 million and $4.5 million, respectively.
Adjusted EBITDA:
Adjusted EBITDA1 was $9.2 million for the three months ended March 31, 2026 compared to $14.1 million for the prior year period.
Free Cash Flow:
Free cash flow was $0.3 million compared to $5.2 million in the prior year quarter. Free cash flow decreased by $4.9 million primarily due to a decrease in gross profit before fair value adjustments of $5.3 million.
Strategic Business Update
Plant Propagation:
On February 3, 2026, Aurora and its wholly owned subsidiary entered into a definitive agreement with Bevo Agtech Inc and Bevo Farms Ltd. pursuant to which, among other things, Aurora agreed to exchange all of its common shares of Bevo for preferred shares of Bevo. On February 17, 2026, the transaction closed, resulting in the disposal of the Company's 50.1% ownership interest in Bevo and loss of control. The financial results of Bevo are no longer consolidated in Aurora's financial statements subsequent to the closing of the transaction.
Safari Flower Company Acquisition:
On April 15, 2026, the Company acquired Safari Flower Company ("Safari"), through a share purchase acquisition, for total consideration of $26.5 million, subject to customary closing adjustments. The consideration is composed of $15 million in cash and 2,417,180 Common Shares with an approximate fair value of $11.5 million. Included in the total consideration is contingent consideration totaling $2 million upon satisfying certain GMP certifications.
The acquisition of Safari provides the Company with a 59,000 square foot EU-GMP certified indoor cultivation and manufacturing facility to supply cannabis to key international markets while reducing reliance on third party purchases.
Fiscal Full Year 2027 Outlook:
Our outlook reflects the strategic changes we have made in exiting our low margin Canadian Consumer and Plant Propagation businesses, which will allow the Company to reallocate resources to focus on global medical cannabis. We believe this is our highest return opportunity to create value.
Over the next few quarters, we are purposely investing in our international business through strategic sales initiatives and EU GMP capacity expansion to support growth in our most profitable markets. These efforts are expected to help offset the impact of margin reductions in our Canadian medical business, following the reduction in government reimbursed pricing, effective April 1, 2026.
Total Net Revenue1 is expected to decline and be more in line with our Cannabis Net Revenue results in fiscal year 2025, following the changes in Canadian medical partially offset by international growth, driven by Germany and Poland. Adjusted Gross Margin before FV adjustments1 are expected to be in the mid to high fifties, driven by higher revenue contributions from Europe and the exit from the lower margin businesses. These benefits will partially offset lower margins in Canadian Medical. Adjusted SG&A1 is expected to remain broadly in line with the prior fiscal year. Adjusted EBITDA1 is expected to vary quarter over quarter, leading to lower annual adjusted EBITDA1 compared to the prior fiscal year. This change in expectations is due to the revisions in reimbursed pricing that drive lower net revenue and adjusted gross profits contributions. Key Quarterly Financial Results
($ thousands)
Three months ended
March 31, 2026
December 31, 2025
$ Change
% Change
March 31, 2025
$ Change
% Change
Financial Results(3)
Net revenue (1)
84,816
82,893
1,923
2 %
76,768
8,048
10 %
Medical cannabis net revenue (1)
77,096
76,247
849
1 %
67,776
9,320
14 %
Consumer cannabis net revenue (1)
3,645
5,160
(1,515)
(29 %)
8,166
(4,521)
(55 %)
Adjusted gross margin before FV adjustments on
total cannabis net revenue(1)
60 %
66 %
N/A
(6 %)
65 %
N/A
(5 %)
Adjusted gross margin before FV adjustments on medical
cannabis net revenue(1)
66 %
69 %
N/A
(3 %)
71 %
N/A
(5 %)
Adjusted gross margin before FV adjustments on
consumer cannabis net revenue(1)
22 %
28 %
N/A
(6 %)
27 %
N/A
(5 %)
Adjusted SG&A expense(1)
40,254
34,867
5,387
15 %
35,403
4,851
14 %
Adjusted EBITDA (1)
9,227
18,371
(9,144)
(50 %)
14,056
(4,829)
(34 %)
Adjusted net income (1)
5,581
11,711
(6,130)
(52 %)
15,272
(9,691)
(63 %)
Free cash flow (1)
316
18,569
(18,253)
(98 %)
5,249
(4,933)
(94 %)
Balance Sheet
Working capital (1)
330,523
299,901
30,622
10 %
367,465
(36,942)
(10 %)
Cannabis inventory and biological assets (2)
169,629
191,064
(21,435)
(11 %)
193,980
(24,351)
(13 %)
Total assets
601,087
775,292
(174,205)
(22 %)
852,666
(251,579)
(30 %)
(1)
These terms are defined in the "Cautionary Statement Regarding Certain Non‑GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures.
(2)
Represents total biological assets and inventory, exclusive of merchandise, accessories, supplies and consumables.
(3)
Results shown are from continuing operations. On February 17, 2026, the Company completed the divestiture of its 50.1% ownership interest in Bevo. As such, Bevo has been excluded from the Company's Q4 2026 continuing results, along with comparative figures, due to its classification as a discontinued operation.
Conference Call
Aurora will host a conference call today, Thursday, June 11, 2026, to discuss these results. Miguel Martin, Chief Executive Officer, and Simona King, Chief Financial Officer, will host the call starting at 8:00 a.m. Eastern time | 6:00 a.m. Mountain Time. A question and answer session will follow management's presentation.
DATE:
Thursday, June 11, 2026
TIME:
8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time
WEBCAST:
Click Here
About Aurora Cannabis
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Statements
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's fiscal 2026 results; statements under the heading "Fiscal Full Year 2027 Outlook ", including, but not limited to, those related to expectations for net revenue, adjusted gross margin before FV adjustments, adjusted EBITDA, and adjusted SG&A; statements regarding the Company's long-term outlook, ability to respond to changing global market dynamics and ability to mitigate the impact of margin reductions in the Canadian medical business; statements regarding the Company's global medical cannabis leadership and anticipated growth in the Company's international medical business; and statements regarding the Company's conference call to discuss results.
These forward-looking statements are only predictions. Forward-looking information or statements contained in this news release have been developed based on the Company and its management's good faith assumptions relating to the financial, market, regulatory and other relevant environments that will exist and affect the Company's business and operations in the future. Forward-looking information and statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management at the date the statements are made including, among other things, assumptions about: development costs remaining consistent with budgets; the ability to manage anticipated and unanticipated costs; access to favorable equity and debt capital markets; the ability to raise sufficient capital to advance the business of the Company; favorable operating and economic conditions; political and regulatory stability; obtaining and maintaining all required licenses and permits; receipt of governmental approvals and permits; sustained labour stability; stability in financial and capital goods markets; favorable production levels and costs from the Company's operations; the pricing of various cannabis products; the level of demand for cannabis products; the availability of third-party service providers and other inputs for the Company's operations; and the Company's ability to conduct operations in a safe, efficient, and effective manner. The Company does not give any assurance that the assumptions on which forward-looking information or statements are based will prove to be correct, or that the Company's business or operations will not be affected in any material manner by these or other factors not foreseen or foreseeable by the Company or management or beyond the Company's control. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete construction projects and facilities improvements, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crisis ,and other risks as set out under the heading "Risk Factors" in the Company's annual information form dated June 11, 2026 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
Non-GAAP Measures
This news release contains reference to certain financial performance measures that are not recognized or defined under IFRS (termed "Non-GAAP Measures"). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Non-GAAP Measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company's operating results, underlying performance and prospects in a manner similar to Aurora's management. Accordingly, these non-GAAP Measures are intended to provide additional information and to assist management and investors in assessing financial performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The information included under the heading "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" in the FY26 Q4 MD&A is incorporated by reference into this news release. The MD&A is available on the Company's issuer profiles on SEDAR+ at www.sedarplus.com and on the U.S. Securities and Exchange Commission's (the "SEC") EDGAR website at www.sec.gov.
Net Revenue, Adjusted Gross Profit and Margin
Net revenue, adjusted gross profit before FV adjustments, and adjusted gross margin before FV adjustments are Non-GAAP Measures and can be reconciled with revenue, gross profit and gross margin, the most directly comparable GAAP financial measures, respectively, as follows:
($ thousands)
Three months ended
Years ended
March 31, 2026
December 31, 2025
March 31, 2025
March 31, 2026
March 31, 2025
Medical cannabis net revenue(1)
Canadian medical cannabis net revenue
28,314
28,250
26,751
112,116
107,432
International medical cannabis net revenue
48,782
47,997
41,025
176,524
137,010
Total medical cannabis net revenue(1)
77,096
76,247
67,776
288,640
244,442
Consumer cannabis net revenue(1)
3,645
5,160
8,166
23,548
40,033
Wholesale bulk cannabis net revenue(1)
4,075
1,486
826
8,405
4,436
Total net revenue(1)
84,816
82,893
76,768
320,593
288,911
(1)
These terms are defined in the "Cautionary Statement Regarding Certain Non‑GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures.
Adjusted EBITDA
The following is the Company's adjusted EBITDA:
($ thousands)
Three months ended
Years ended
March 31, 2026
December 31, 2025(3)
March 31, 2025(3)
March 31, 2026
March 31, 2025(3)
Net income (loss) from continuing operations
(27,566)
6,317
(12,128)
(58,619)
27,050
Income tax expense (recovery)
(538)
97
3,285
2,095
4,245
Other expense (income)
1,673
2,322
(11,925)
9,862
(20,861)
Share-based compensation
689
(551)
3,786
7,293
12,930
Depreciation and amortization
3,871
4,583
3,379
16,228
15,430
Business development costs
850
443
624
1,975
3,435
Inventory and biological assets fair value and
impairment adjustments
20,487
1,306
21,953
50,419
(20,969)
Business transformation costs (1)
9,761
3,854
5,082
24,555
19,610
Adjusted EBITDA (2)
9,227
18,371
14,056
53,808
40,870
(1)
Business transformation related charges include costs related to closed facilities, certain IT project costs, sublease income, severance and retention costs in connection with the exit of the consumer market, legal provisions and costs associated with the retention of certain medical aggregators.
(2)
Adjusted EBITDA is defined in the "Cautionary Statement Regarding Certain Non‑GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures.
(3)
Prior period comparatives were adjusted to include the adjustments for markets under development, business transformation costs and non-recurring charges related to non-core bulk cannabis wholesale to be comparable to the current period presentation.
Adjusted Net Income
The following is the Company's adjusted net income (loss):
($ thousands)
Three months ended
Years ended
March 31, 2026
December 31, 2025
March 31, 2025
March 31, 2026
March 31, 2025
Net income (loss) from continuing operations
(27,566)
6,317
(12,128)
(58,619)
27,050
Inventory and biological assets fair value and
impairment adjustments
20,487
1,306
21,953
50,419
(20,969)
Business development costs
850
443
624
1,975
3,435
Impairment of property, plant and equipment
2,246
4
—
2,775
(696)
Impairment of intangible assets and goodwill
—
—
—
13,186
—
Deferred tax expense - impairment of intangible
assets and goodwill
—
—
—
5,856
—
Business transformation costs (1)
9,564
3,641
4,823
23,746
18,401
Adjusted net income (2)
5,581
11,711
15,272
39,338
27,221
(1)
Business transformation costs include certain IT project costs, severance and retention costs in connection with the exit of the consumer market, legal provision and costs associated with the retention of certain medical aggregators.
(2)
Adjusted net income is defined in the "Cautionary Statement Regarding Certain Non‑GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures
Adjusted SG&A
Adjusted SG&A is a Non-GAAP Measure and can be reconciled with sales and marketing and general and administrative expenses, the most directly comparable GAAP financial measure, as follows:
Three months ended
Years ended
($ thousands)
March 31, 2026
December 31, 2025
March 31, 2025
March 31, 2026
March 31, 2025
General and administration
29,540
23,861
25,078
106,567
91,323
Sales and marketing
16,022
14,860
15,407
59,641
56,170
Business transformation costs (2)
(5,308)
(3,854)
(5,082)
(20,105)
(19,610)
Adjusted SG&A (1)
40,254
34,867
35,403
146,103
127,883
(1)
Adjusted SG&A is defined in the "Cautionary Statement Regarding Certain Non‑GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures.
(2)
Business transformation costs include certain IT project costs, severance and retention costs in connection with the business transformation plan and costs associated with the consumer channel exit
Free Cash Flow
The table below outlines free cash flow for the periods ended:
Three months ended
Years ended
($ thousands)
March 31, 2026
December 31, 2025
March 31, 2025
March 31, 2026
March 31, 2025
Cash provided by (used in) operating activities
from continuing operations before changes in
non-cash working capital
(9,410)
9,517
(2,969)
1,386
4,764
Changes in non-cash working capital
11,823
10,573
9,736
(9,214)
14,205
Net cash provided by (used in) operating
activities from continuing operations
2,413
20,090
6,767
(7,828)
18,969
Less: maintenance capital expenditures(1)
(2,097)
(1,521)
(1,518)
(6,425)
(8,084)
Free cash flow(2)
316
18,569
5,249
(14,253)
10,885
(1)
Maintenance capital expenditures are comprised of costs to sustain facilities, machinery and equipment in working order to support operations and excludes discretionary investments for revenue growth.
(2)
Free cash flow is defined in the "Cautionary Statement Regarding Certain Non‑GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures.
Working Capital
Working capital is a Non-GAAP Measure and can be reconciled with total current assets and total current liabilities, the most directly comparable GAAP financial measure, as follows:
Profit from the Green Wave: Top Cannabis Stocks to WatchAurora Cannabis NASDAQ: ACB reported a stronger fiscal 2026 performance than it had forecast, driven by growth in global medical cannabis, while warning that fiscal 2027 will be a “reset year” as Canadian medical reimbursement changes weigh on revenue and margins.
Executive Chairman and CEO Miguel Martin said fiscal 2026 was “a strong year for Aurora,” with net revenue meaningfully above the company’s outlook and adjusted EBITDA above the midpoint of its guidance range. He said the results reflected Aurora’s focus on medical cannabis in nationally legal markets and disciplined financial management.
Get Aurora Cannabis alerts:
The Cannabis Sector: Profitability Takes Center StageFor the fiscal year ended March 31, 2026, Aurora reported net revenue of CAD 321 million, up 11% from the prior year and CAD 8 million above the top end of its guided range. Martin said about 55% of net revenue was generated outside Canada. Adjusted gross margin rose to 64%, and adjusted EBITDA increased 32% year over year to CAD 54 million. The company ended the year with CAD 165 million in cash and cash equivalents and no debt.
Medical Cannabis Drives Fourth-Quarter Growth CFO Simona King said fourth-quarter net revenue rose 10% year over year to CAD 84.8 million, driven by 14% growth in global medical cannabis revenue, including a 19% increase internationally. She said 58% of total net revenue in the quarter was generated outside Canada.
Aurora Cannabis Earnings Reveal a Turning Tide for the StockMedical cannabis net revenue rose 14% to CAD 77.1 million, a record for combined Canadian and international net revenue, according to King. Medical cannabis represented 91% of total net revenue, up from 88% in the prior-year quarter. Adjusted gross margin for medical cannabis was 66%, down from the prior year due to sales of lower-margin products and strategic price reductions in certain markets.
Adjusted EBITDA for the quarter was CAD 9.2 million, while adjusted net income was CAD 5.6 million, compared with CAD 16.3 million in the prior-year period. King said the decline in adjusted net income primarily reflected higher adjusted SG&A, lower foreign exchange gains and lower interest income.
Consumer cannabis net revenue fell to CAD 3.6 million from CAD 8.2 million as the company shifted flower toward higher-margin medical cannabis and moved to wind down parts of the Canadian consumer segment.
Aurora Exits Lower-Margin Businesses Martin said Aurora initiated its exit from certain lower-margin Canadian consumer markets during the fiscal fourth quarter, with completion expected by the end of September. He said the transition had one-time cash impacts in the quarter but would allow the company to redirect resources toward global medical cannabis.
The company also divested its lower-margin plant propagation business by selling its controlling stake in Bevo. King said the fiscal 2027 outlook reflects these strategic actions, which are intended to reallocate resources to “more attractive global medical cannabis markets.”
In April, Aurora acquired Safari Flower Company, a Canadian-based EU GMP-certified cannabis cultivator and manufacturer, for approximately CAD 26.5 million. Martin said the acquisition expands Aurora’s EU GMP capacity and supports supply of flower to international markets, particularly Germany. He said Safari’s 59,000-square-foot indoor cultivation and manufacturing facility in Ontario aligns with Aurora’s existing sites and is expected to contribute positive adjusted EBITDA in fiscal 2027, with incremental benefits in fiscal 2028 and beyond.
During the question-and-answer session, Martin said Safari was “absolutely accretive from the get-go,” adding that Aurora sees upside from introducing its genetics and cultivation practices.
Germany, Poland and Australia Remain Key International Markets Martin said Germany was the largest contributor to Aurora’s double-digit international revenue growth in fiscal 2026, supported by commercial execution and the company’s reputation with wholesalers, distributors and pharmacists. He said Aurora has seen increased price pressure as new competitors enter the market, but that pressure has largely been concentrated in the value segment.
Because Aurora’s volume is weighted toward core and premium products, Martin said the company has maintained its leading market share in Germany. He also noted that two of Aurora’s proprietary cultivars ranked No. 1 and No. 3 by sales during the quarter.
Aurora is one of three active in-country producers of medical cannabis in Germany, Martin said, and the company is expanding its Leuna facility. The expansion is expected to be completed in the first half of fiscal 2027 and, along with proprietary cultivars, is expected to double annual flower output at the site.
In Poland, Martin said Aurora holds the No. 1 market share position and successfully navigated a shift from telehealth-driven prescribing to clinic-based prescribing. Poland was the second-largest contributor to international growth after Germany, he said. In Australia, Aurora is working to shift its sales mix toward core and premium products amid interest from physicians and patients.
Martin also pointed to potential market developments in France, Ukraine, Switzerland, Spain and Austria, saying Aurora’s GMP-certified portfolio positions it to enter new jurisdictions as they come online.
Canadian Reimbursement Changes Weigh on 2027 Outlook King said fiscal 2027 will be shaped by changes to reimbursed pricing in Canadian medical cannabis, only partially offset by international growth. Total net revenue is expected to decline and be more in line with Aurora’s cannabis net revenue results in fiscal 2025, with growth driven by Germany and Poland partly offsetting the Canadian changes.
Adjusted gross margins are expected to be in the mid-to-high 50% range. King said higher revenue contributions from Europe and the exit from lower-margin businesses will partially offset lower Canadian medical margins following the reimbursement-rate reduction. Adjusted SG&A is expected to remain broadly in line with fiscal 2026, while annual adjusted EBITDA is expected to be lower than the prior fiscal year.
In response to a question from TD Cowen analyst Derek Lessard, Martin said the reimbursement change effective April 1 represents about a 30% reduction in the reimbursed rate for affected products. King said Aurora does not break out adjusted gross margins between Canadian and international medical businesses, but the Canadian reimbursement change is a driver of the company’s margin outlook.
Martin said early patient patterns have not changed materially since the reimbursement shift, telling ROTH Capital Partners analyst Bill Kirk that Aurora has not seen major changes in format or price-point choices so far.
Company Evaluates U.S. Opportunities Martin said Aurora is encouraged by recent cannabis rescheduling developments in the U.S. and is considering reevaluating its U.S. strategy, but added that the company has “nothing definitive to announce” amid ongoing regulatory uncertainty.
During the Q&A, Martin said potential opportunities could include research partnerships, medical cannabis partnerships applying GMP standards, and possible import-export pathways depending on future regulations. He said the research opening in the U.S. could be significant for Aurora given its experience in medical cannabis.
Martin closed the call by saying Aurora is focused on converting what it views as a CAD 9 billion global medical cannabis opportunity into sustained shareholder returns, supported by investments in market share, GMP capacity, product innovation and international expansion.
About Aurora Cannabis NASDAQ: ACBAurora Cannabis Inc NASDAQ: ACB is a Canadian licensed producer of medical and consumer cannabis products headquartered in Edmonton, Alberta. Established in 2013, the company operates under Health Canada's regulations to cultivate, process and distribute a range of cannabis-based offerings. Since its initial public listing in 2017, Aurora has grown into one of the country's largest growers by cultivation capacity and production output.
The company's core business spans the cultivation of dried flower, the extraction of cannabis oils and the development of value-added products such as softgels, capsules and topical treatments.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Aurora Cannabis Right Now?Before you consider Aurora Cannabis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurora Cannabis wasn't on the list.
While Aurora Cannabis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.
Aurora Cannabis reported Q4/FY2026 results largely in line with expectations previously outlined by management. In recent months, the company has made the strategic decision to exit its lower margin consumer cannabis and plant propagation operations and focus on the growing European medical cannabis market. However, FY2027 will be impacted by adverse regulatory changes in the Canadian medical cannabis market. As a result, sales and margins are expected to decline quite meaningfully this year.
Key Takeaways Aurora beat earnings and revenue estimates, but its call focused on margins and global medical growth.Canadian reimbursement cuts are expected to pressure FY27 revenues and adjusted gross profit.Aurora is exiting lower-margin consumer markets while investing in EU-GMP capacity and Germany growth. Aurora Cannabis Inc. (ACB - Free Report) used its fourth-quarter fiscal 2026 earnings call to frame the year as proof that its medical-first model is working, even as management prepared investors for a more difficult fiscal 2027. The company beat the Zacks Consensus Estimate for both earnings and revenues, but the discussion centered more on margin mix, reimbursement pressure and international expansion than on the quarter itself.
Executive chairman and CEO Miguel Martin emphasized that Aurora is narrowing its focus on globally regulated medical cannabis markets, where he said that the company has stronger competitive positioning and better returns. That message carried through the prepared remarks and the analyst Q&A.
ACB Leans Harder Into Medical CannabisMartin said that fiscal 2026 validated Aurora’s strategy of building around medical cannabis in Canada, Germany, Australia and Poland, with 55% of annual net revenues generated outside Canada. He described medical cannabis as the company’s most durable and attractive segment and said that its GMP-certified infrastructure gives it a meaningful edge in regulated export markets.
That strategic emphasis showed up in the numbers. Annual net revenues rose 11% to $320.6 million, while global medical cannabis net revenues reached a record $288.6 million, up 18% year over year. Fiscal fourth-quarter net revenues increased 10% to $84.8 million, and medical cannabis revenues climbed 14% to $77.1 million.
ACB also reported quarterly adjusted earnings of $0.07 per share, compared with the Zacks Consensus Estimate for a loss of $0.07 per share, resulting in an earnings surprise of 200%. Revenues of $65.1 million topped the Zacks Consensus Estimate of $55.3 million.
Aurora Faces Canada Reimbursement ResetThe most important forward-looking issue on the call was not demand, but pricing. Martin said that a change in Canada’s federal reimbursement program took effect on April 1 and cut the reimbursed rate on covered products by about 30%, creating an immediate hit to the top line in that part of the business.
Aurora expects the fiscal 2027 adjusted gross margin in the mid- to high-50% range, below the 64% achieved in fiscal 2026 and the 60% posted in the fourth quarter of fiscal 2026. CFO Simona King said that lower reimbursed pricing in Canadian medical is expected to pressure revenues and adjusted gross profit this year.
Management did not describe a demand collapse. In response to a ROTH Capital Partners question, Martin said that patient behavior has not changed materially so far, with no major shift in product format or price point yet visible.
ACB Reallocates Capital Toward Higher-Margin MarketsAurora’s answer to that Canadian headwind is portfolio reshaping. Martin said that the company is exiting lower-margin Canadian consumer cannabis markets by the end of September and has already divested its controlling stake in plant propagation business Bevo. King said that those moves should free resources for global medical cannabis, which management sees as its highest-return opportunity.
The company also closed the acquisition of Safari Flower Company in April for $26.5 million. Management said that the EU-GMP-certified facility adds critical production capacity for international flower markets and should contribute to adjusted EBITDA in fiscal 2027, with larger benefits beyond that.
That mix shift is already visible in the quarter. Consumer cannabis revenues fell to $3.6 million from $8.2 million a year earlier as Aurora deliberately redirected flower toward medical channels.
Aurora Sees Germany as Main Growth EngineGermany remained the centerpiece of the international discussion. Martin said that Germany was the biggest contributor to international growth in fiscal 2026, supported by stronger execution, a broader product mix and Aurora’s reputation with wholesalers, distributors and pharmacists. He has also added that the company still holds its leading position because most of its business sits in the core and premium segments, wherein price pressure has been less intense than in value products.
Management is backing that view with capacity investment. Martin said that Aurora’s Leuna facility expansion in Germany is expected to be completed in the first half of fiscal 2027 and should double annual flower output there. Safari adds supply from Canada into EU-GMP channels.
In Q&A, Martin told analysts from TD Cowen and Canaccord Genuity that Germany’s regulatory and quality standards remain a barrier to entry. He argued that Aurora’s genetics, consistency, disease resistance and GMP experience create a moat that should matter more as standards tighten.
ACB Stays Watchful on the U.S.The call also brought a measured update on the United States. Martin said that Aurora is encouraged by U.S. cannabis rescheduling developments and is re-evaluating its strategy, but he stressed that the company has nothing definitive to announce yet.
In response to an ATB Cormark question, Martin outlined three possible areas of opportunity: research partnerships, medical-focused commercial partnerships and eventual import-export openings if federal rules evolve that way. He was more explicit in Q&A than in prepared remarks, but still careful not to commit capital or timing.
The tone suggested interest without near-term dependence. Management presented the United States as an optional upside, while keeping the core operating plan centered on Canada, Europe, Australia and New Zealand.
Aurora Enters FY27 in Investment ModeKing said that fiscal 2027 would be a reset year. Total net revenues are expected to decline and track more closely with fiscal 2025 cannabis revenues, while adjusted EBITDA is also expected to come in below fiscal 2026 as Canadian reimbursement pressure outweighs near-term international gains.
Still, management’s posture was not defensive. Martin repeatedly framed the coming year as a period of targeted investment in sales initiatives, EU-GMP capacity and product innovation to support the next phase of international growth.
What Zacks Signals Are SayingACB currently carries a Zacks Rank #3 (Hold), along with a Value Score of B, a Growth Score of C, a Momentum Score of B and a VGM Score of B. Under the Zacks framework, the above-mentioned rank points to a more balanced near-term outlook than a bullish one, while the B grades in Value, Momentum and VGM indicate some supportive characteristics relative to peers.
The Style Scores document says the strongest setups tend to come from Zacks Rank #1 (Strong Buy) or #2 (Buy) stocks paired with A or B Style Scores, while Rank #3 stocks can still be held, with the same grade hierarchy applying. That leaves ACB in the middle ground after the quarter, with favorable style marks in some areas but a rank that can still change as earnings estimate revisions adjust following the latest results. You can see the complete list of today’s Zacks #1 Rank stocks here.
After years of restructuring, dilution, asset sales, and losses, investors remain sharply divided on whether Canopy Growth Corporation (CGC 0.49%) is finally stabilizing or simply extending a long decline.
Indeed, the next 12 months will likely provide an answer to that question.
Here are three realistic scenarios for where Canopy Growth stock could go next.
Image source: Getty Images.
Scenario 1: Canopy finally stabilizes This is the bullish case. Canopy has spent the past several years cutting costs, restructuring operations, and narrowing losses. In fiscal Q3 2026 (ended Dec. 31), the company reported revenue of $75 million Canadian dollars ($55 million) while adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) losses narrowed to about CA$3 million, marking its third consecutive quarter of improvement.
This isn't trivial because profitability has always been the central issue surrounding Canopy Growth.
The company also ended September 2025 with about CA$298 million in cash and cash equivalents, exceeding debt balances by roughly CA$70 million after making $50 million in debt prepayments.
Operationally, Canopy is finally showing pockets of growth again. Canada adult-use cannabis revenue increased 8% year over year in Q3, while medical cannabis revenue rose 15%. Management now believes the company can achieve positive adjusted EBITDA during fiscal 2027.
If Canopy can sustain revenue growth while maintaining cost discipline, investors may begin treating the company less like a distressed cannabis operator and more like a turnaround story.
Of course, that would require continued margin improvement, stable Canadian cannabis pricing, and stronger cash flow trends.
Under that scenario, the stock could recover meaningfully from current depressed levels.
Scenario 2: The company survives, but the stock goes nowhere This may be the most realistic outcome. Despite operational improvements, Canopy still faces structural problems that haven't disappeared.
The Canadian cannabis market remains oversupplied and intensely competitive. Pricing pressure continues to hurt margins across the industry, while regulatory delays limit meaningful U.S. expansion opportunities.
Meanwhile, Wall Street analysts still expect Canopy Growth to remain unprofitable for the foreseeable future, with some forecasts projecting only modest or little changed revenue growth over the next fiscal year.
That creates a difficult setup for shareholders. Canopy may ultimately survive financially without necessarily generating the type of earnings growth needed to justify a sustained stock rally.
This scenario would likely involve periodic dilution, continued restructuring, slow revenue growth, and ongoing volatility tied to cannabis legalization developments.
In other words, the company survives, but shareholders are stuck with dead money.
Today's Change
(
-0.49
%) $
-0.01
Current Price
$
1.00
Scenario 3: Another major breakdown This is the bearish case. Canopy has already undergone multiple restructurings, but the company still operates in an industry with weak pricing power, limited profitability, and uncertain regulation.
If Canadian cannabis pricing deteriorates further or consumer demand weakens, Canopy could quickly find itself back under financial pressure despite recent balance-sheet improvements. The company has still reported significant losses in fiscal 2026, including a Q3 net loss of about CA$63 million.
The cannabis sector also remains heavily dependent on investor sentiment. If broader market conditions weaken or capital becomes more expensive again, speculative cannabis stocks, many of which are still in prominent marijuana exchange-traded funds (ETFs), could face another major sell-off similar to previous industry downturns.
There's also execution risk. Canopy continues betting heavily on product innovation, premium brands, medical cannabis expansion, and international markets. But international cannabis sales actually declined sharply during parts of fiscal 2026 because of European supply chain problems.
If those operational challenges persist while revenue growth stalls, the market could begin to question whether the turnaround is truly sustainable.
The bottom line is simple: Canopy Growth long ago stopped being the hypergrowth marijuana stock story. Today, it's a restructuring and survival story.
The company has improved its balance sheet, narrowed losses, and stabilized parts of its business. But profitability remains elusive, the cannabis industry is saturated, and investor confidence remains fragile.
Top Canadian Cannabis Stocks to Watch in May 2026 Canadian cannabis stocks remain active in May 2026. Investors continue watching the sector for growth opportunities and reform catalysts. In addition, many traders expect future federal progress in the United States. That possibility has increased interest across the entire cannabis market. Recent headlines surrounding possible cannabis rescheduling also boosted momentum in leading names.
At the same time, volatility remains high in the cannabis sector. Therefore, traders should continue using technical analysis and proper risk management. Many cannabis stocks still trade well below previous highs. However, improving revenue trends and international expansion continue to support long-term optimism. Three Canadian cannabis companies stand out this month. These companies are Tilray Brands, Canopy Growth, and Village Farms International.
[Read More] Top Marijuana Companies Building Momentum In 2026
3 Canadian Marijuana Stocks Investors Are Watching Right Now Tilray Brands (NASDAQ: TLRY) Canopy Growth (NASDAQ: CGC) Village Farms International (NASDAQ: VFF) Tilray Brands (NASDAQ: TLRY) Tilray remains one of the largest cannabis companies in Canada. The company also has a growing international footprint. In addition, Tilray operates across cannabis, beverages, wellness products, and pharmaceutical distribution. That diversification continues to set it apart from many competitors. Tilray currently holds leading market share positions across several cannabis categories in Canada.
The company’s largest United States presence comes from its beverage alcohol operations. Tilray owns several craft beer brands across multiple states. Meanwhile, the company continues positioning itself for future U.S. cannabis legalization. Tilray does not currently operate U.S. dispensaries directly because of federal restrictions. However, the company maintains strategic exposure through partnerships and acquisitions. Investors continue watching Tilray closely because of its broad international operations. Furthermore, Tilray remains active throughout Europe’s medical cannabis market. The company has also expanded into hemp wellness and pharmaceutical distribution businesses. That diversification may help reduce sector volatility over time. As a result, many investors still consider Tilray one of the leading Canadian cannabis stocks.
Tilray recently reported strong fiscal third-quarter 2026 results. The company posted quarterly revenue of approximately $207 million. That figure represented an 11% year-over-year increase. Gross profit also improved during the quarter. In addition, Tilray reported expanding cannabis revenue and strong international growth.
International cannabis revenue increased sharply compared to last year. The company also significantly reduced overall net losses. Furthermore, management continues focusing on operational efficiency and cost reductions. Tilray’s distribution business also contributed positively during the quarter. However, the beverage segment still faced some pressure. Rising competition within the cannabis industry also remains a challenge. Despite those issues, investors reacted positively to improving growth trends. Analysts continue to closely monitor future profitability and U.S. reform developments. Tilray shares remain volatile, but many traders still watch the stock closely for momentum opportunities. Therefore, TLRY remains a top Canadian cannabis stock to watch in May 2026.
[Read More] 3 Top Picks For Marijuana Stocks Investors To See Profits In 2026
Canopy Growth (NASDAQ: CGC) Canopy Growth remains one of the most recognized cannabis companies worldwide. The company built its reputation during the early cannabis boom years. Today, Canopy continues restructuring operations while focusing on efficiency and premium cannabis products. The company maintains strong medical and adult-use cannabis operations across Canada. In addition, Canopy continues expanding internationally through medical cannabis distribution.
Canopy’s largest United States exposure comes through strategic partnerships and cannabis-related investments. The company has positioned itself carefully for future U.S. legalization opportunities. However, Canopy does not currently operate active U.S. dispensaries directly. Instead, management continues focusing on brand development and international expansion. Canopy’s Canadian cannabis business remains its core operation today. The company continues emphasizing premium flower, pre-rolls, and vaporizer products. In addition, Canopy has significantly strengthened its medical cannabis business. Medical cannabis sales in Canada improved because of rising insured patient demand. Investors continue watching Canopy because of its strong brand recognition. Furthermore, the company still maintains one of the most recognized names in the global cannabis sector.
Canopy recently released its fiscal 2026 quarterly financial results. The company reported improving cannabis revenue trends across several business segments. Canadian medical cannabis revenue increased compared to last year. Adult-use cannabis revenue also improved because of stronger product demand.
However, profitability challenges remain a major concern for investors. Gross margins declined compared to prior periods. Operating losses also remained elevated during the quarter. Nevertheless, management continues to implement restructuring and cost reduction initiatives. The company also maintains a significant cash reserve position. That liquidity may help support operations during the ongoing turnaround effort. Investors continue watching whether Canopy can achieve sustainable profitability in future quarters. In addition, future U.S. cannabis reform could provide another catalyst for the stock. CGC remains highly speculative, but traders continue monitoring the company closely. Therefore, Canopy Growth stays on many cannabis watchlists for May 2026.
[Read More] Top Canadian Cannabis Penny Stocks to Watch This Month
Village Farms International (NASDAQ: VFF) Village Farms International continues to gain attention within the cannabis industry. The company originally built its business through greenhouse agriculture operations. Today, Village Farms operates one of Canada’s leading cannabis cultivation businesses through Pure Sunfarms. In addition, the company maintains strong international export operations. Village Farms has also expanded into medical cannabis opportunities across Europe and other markets.
The company’s largest United States presence still comes from agricultural operations rather than cannabis dispensaries. Village Farms currently does not operate U.S. cannabis dispensaries directly. However, management continues preparing for possible future U.S. legalization opportunities. Investors continue to focus on Village Farms due to its greenhouse production expertise. Furthermore, the company benefits from relatively efficient cultivation costs compared to many competitors. Pure Sunfarms continues to hold strong market share positions within Canada’s cannabis market. The company has also aggressively expanded international cannabis exports over the last year. That international growth continues to support investor optimism. As a result, Village Farms has become one of the more closely watched Canadian cannabis companies.
Village Farms recently reported strong first-quarter 2026 financial results. The company generated record quarterly cannabis sales during the period. Total sales increased approximately 27% year over year. Cannabis revenue growth also exceeded many analyst expectations. Gross margins improved significantly compared to prior periods.
Importantly, Village Farms also reported positive earnings from continuing operations. That achievement marked another profitable quarter for the company. International cannabis exports increased sharply during the quarter as well. Management also discussed potential opportunities from future U.S. cannabis reform. In addition, the company continues strengthening its balance sheet and operational efficiency. Investors responded positively to the improving profitability trends. Many traders now view Village Farms as one of the stronger financial performers within the cannabis sector. Therefore, VFF remains one of the top Canadian cannabis stocks to watch in May 2026.
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) expects to release its financial results for the quarter and fiscal year ended March 31, 2026 before financial markets open on June 15, 2026. The Company also announced it plans to file restated financial results for the fiscal years ended March 31, 2025 and March 31, 2024 and to certain of the interim periods therein (the “Refiling”), in conjunction with its filing of.
In the latest close session, Canopy Growth Corporation (CGC - Free Report) was down 5.55% at $0.98. The stock trailed the S&P 500, which registered a daily loss of 0.07%. Elsewhere, the Dow saw an upswing of 0.32%, while the tech-heavy Nasdaq depreciated by 0.51%.
Coming into today, shares of the company had lost 8.77% in the past month. In that same time, the Medical sector lost 2.17%, while the S&P 500 gained 5.58%.
Analysts and investors alike will be keeping a close eye on the performance of Canopy Growth Corporation in its upcoming earnings disclosure. The company's earnings report is set to go public on May 29, 2026. In that report, analysts expect Canopy Growth Corporation to post earnings of -$0.06 per share. This would mark year-over-year growth of 93.62%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $53.26 million, up 17.56% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of -$0.36 per share and a revenue of $210.58 million, demonstrating changes of +87.92% and +8.94%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Canopy Growth Corporation. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Canopy Growth Corporation is currently a Zacks Rank #2 (Buy).
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 156, finds itself in the bottom 37% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Canopy Growth Corporation (CGC - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this company have returned -13.2% over the past month versus the Zacks S&P 500 composite's +3.3% change. The Zacks Medical - Products industry, to which Canopy Growth belongs, has lost 11.1% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Canopy Growth is expected to post a loss of $0.06 per share, indicating a change of +93.6% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The consensus earnings estimate of -$0.36 for the current fiscal year indicates a year-over-year change of +87.9%. This estimate has remained unchanged over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $0.11 indicates a change of +69.4% from what Canopy Growth is expected to report a year ago. Over the past month, the estimate has remained unchanged.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Canopy Growth.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Canopy Growth, the consensus sales estimate for the current quarter of $53.26 million indicates a year-over-year change of +17.6%. For the current and next fiscal years, $210.58 million and $278.96 million estimates indicate +8.9% and +32.5% changes, respectively.
Last Reported Results and Surprise HistoryCanopy Growth reported revenues of $53.47 million in the last reported quarter, representing a year-over-year change of +0.1%. EPS of -$0.1 for the same period compares with -$0.76 a year ago.
Compared to the Zacks Consensus Estimate of $50.59 million, the reported revenues represent a surprise of +5.7%. The EPS surprise was -233.33%.
Over the last four quarters, Canopy Growth surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.
ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Canopy Growth is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Canopy Growth. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
